

SINGAPORE POLYTECHNIC  
SCHOOL OF CHEMICAL AND LIFE SCIENCES



DIPLOMA IN BIOMEDICAL SCIENCES  
(MEDICAL TECHNOLOGY)

---

**RNA INTERFERENCE AS POTENTIAL  
ANTIVIRAL TREATMENT AGAINST  
ENTEROVIRUS 71**

---

Project code: DBS0801

TAN SHI MIN	0656993
JONI CHONG CHOY YUE	0636522
MAH KAIQUAN	0636692
AMALINA BTE BASRI	0636241

PROJECT SUPERVISOR: DR. TAN ENG LEE

2008/2009

#### Acknowledgement

The authors of this report would like to express their heartfelt gratitude to those who had provided assistance during the several months.

Firstly, the authors would like to thank the project supervisor Dr. Tan Eng Lee for his readiness and willingness to take on this project. His patience in guidance, encouragement and his invaluable insight are greatly appreciated. The authors would like to thank him for the opportunity to collaborate with him for this project.

Next, the authors would like to thank Mrs. Mark Ong Chye Sun for her eagerness to provide assistance and openness toward the group. The authors would like to thank Mr. Woo Wee Hong for taking time off his busy schedule and his patience in teaching. Heartfelt gratitude is also expressed by the authors to all the lecturers of Diploma in Biomedical Science for their time, care and concern. The authors would also like to express appreciation to the technical support shown by Ms. Ti Kyi Win and Ms. Cheryl Lee.

Finally, the authors would also like to thank the School of Chemical and Life Sciences, Singapore Polytechnic for the support, as well as the provision of funding from Singapore Polytechnic and Singapore Totalisator Board

Thank you all for your efforts to the authors and to the project.

## Abstract

Hand-foot-and-mouth disease (HFMD) is quickly becoming a common childhood disease. HFMD is not usually fatal but when infected by Enterovirus 71 (EV71), one of the causative agents of HFMD, this childhood disease has the potential generate neurological symptoms, complications and even death. As there are currently no effective treatment against EV71, development of an efficient antiviral therapy is important. This study shows the use of RNA interference (RNAi) as a potential antiviral therapy against EV71.

RNAi, a pathway founded by Fire A. in *Caenorhabditis elegans*, is currently one of the most researched pathways due to its potential as an antiviral treatment. The pathway occurs in the cytoplasm, which is suitable for use against EV71 because its replication cycle also takes place in the cytoplasm. Custom-designed small interfering RNAs (siRNA) of three different lengths and concentrations were transfected into Rhabdomyosarcoma (RD) cells to target the 3D polymerase region of the EV71 genome. The lengths of the siRNA used were 19mer, 27mer and 29mer, and the concentrations used were 3nM, 5nM and 10nM. The effectiveness of inhibition of EV71 replication was verified by Western blot and plaque forming unit assays.

The results proved that RNAi could be used as a potential antiviral therapy against EV71, and that the inhibition of EV71 was dependent on the concentration of siRNA transfected. The different lengths of siRNA also affected the efficiency of the viral replication. The results revealed that 19mer siRNA had the weakest inhibitory effects while 29mer had the best inhibitory effects. Using the results from this study, more

assays can be done to provide a numerical representation of the inhibitory effects before proceeding to animal testing.

## Table of Contents

Acknowledgement.....	ii
Abstract.....	iii
Table of Contents.....	iv
List of Figures.....	v
List of Tables.....	vi
1. Introduction .....	1
2. Background .....	3
2.1 Enteroviruses .....	3
2.2 EV71 Clinical Manifestations .....	4
2.3 Genomic Structure of EV71 .....	8
2.4 EV71 Epidemiology .....	12
2.5 Diagnosis of EV71 .....	12
2.6 Treatment for EV71 Infection .....	16
2.7 RNA Interference .....	18
2.8 siRNA Design .....	20
3. Materials and Method .....	24
3.1 Methodology .....	24
3.2 Maintenance of RD Cells .....	24
3.3 Cyro-preservation of RD Cells .....	24
3.4 Design of siRNA .....	26

3.5 Seeding of RD Cells .....	27
3.6 Plaque Forming Unit Assay .....	27
3.7 Cell Viability Plaque Forming Unit Assay .....	29
3.8 Transfection and Infection of RD Cells .....	29
3.9 SDS-PAGE and Western Blot .....	30
4. Results .....	32
4.1 Determination of Viral Titre .....	32
4.2 Protection of RD Cells from EV71-Induced Cytopathic Effects (CPE) ...	33
4.3 Inhibition of EV71 Replication by siRNA .....	36
5. Discussion .....	42
5.1 Problems Encountered .....	42
5.2 RNAi and siRNA .....	42
5.3 Plaque Forming Unit Assay .....	43
5.4 Transfection .....	45
5.5 Cell Viability Plaque Forming Unit Assay .....	46
5.6 Western Blot .....	47
6. Future Developments .....	49
6.1 Transfection Efficiency .....	49
6.2 Inhibition Detection Assay .....	51
6.3 Therapeutic Studies .....	54
6.4 <i>In vivo</i> Studies .....	55
7. Conclusion .....	59
8. References .....	61
9. Appendices .....	69

## List of Figures

Figure 1: Exanthema on the hands .....	5
Figure 2: Exanthema on the feet .....	6
Figure 3: Multiple ulcers on the tongue .....	7
Figure 4: Genomic structure of EV71 .....	9
Figure 5: Electron microscopy of EV71 .....	11
Figure 6: RNAi pathway .....	19
Figure 7: Methodology .....	25
Figure 8: Timeline of methodology .....	31
Figure 9: Plaques from plaque forming unit assay .....	33
Figure 10: Inhibition of EV71-induced CPE .....	35
Figure 11: Cell Viability plaque forming unit assay .....	37
Figure 12: Western blot for VP1 and $\beta$ -actin .....	41
Figure 13: Molecular structure of FITC .....	50
Figure 14: EV71-infected mice .....	56

## List of Tables

Table 1: An overview of the Epidemiology of Hand-Foot-Mouth Disease .....	13
Table 2: List of criteria for design of efficient siRNA .....	23
Table 3: siRNA sequences .....	28
Table 4: Plaque count in the wells infected with EV71 diluted to 1000 times .....	34
Table 5: Student's T tests for cell viability plaque assay .....	38
Table 6: Calculations for plaque forming unit assay .....	44

## 1. Introduction

HFMD is quickly becoming one of the major childhood diseases which can be potentially fatal if the causative agent is EV71 [Hellen, 1995]. Infecting mainly children, EV71 is now a virus which raises awareness and alarm for many parents due to its ability to cause neurological symptoms [Kuo *et al.*, 2002]. There had been many reports of EV71 outbreaks and deaths around the world since the 1970s and more recently in the past 20 years, the Asia-Pacific regions [Cardosa *et al.*, 2003]. Unfortunately, the current treatment only addresses the symptoms [Tan *et al.*, 2006]. There is no specific EV71 antiviral available to date [Tan *et al.*, 2006]. In light of the pressing EV71 situation faced by the Asia-Pacific region, development for an effective antiviral is crucial.

Since its discovery, the RNAi pathway is currently one of the most researched pathways due to its potential to be used as an antiviral treatment. This pathway occurs in the cytoplasm of almost all eukaryotic cells [Dykxhoorn *et al.*, 2006]. For this reason, RNAi is suitable for usage as an antiviral against EV71 because EV71 replicates in the cytoplasm. RNAi is triggered when the cell encounters a double-stranded RNA molecule, such as that of a viral RNA [Dykxhoorn *et al.*, 2006]. The cell uses this pathway to process the RNA and using the processed RNA to find other RNA molecules that are complementary to it and cleave it [Dykxhoorn *et al.*, 2006]. If the RNA encountered by the cell belongs to a virus, the cell uses this pathway to look for similar RNA molecules that has complementary sequences and cleaves it [Dykxhoorn *et al.*, 2006]. By cleaving the RNA molecules, the virus will not be able to replicate successfully and the cell is protected from infection.

One of the objectives of this study is to use siRNA and RNAi against EV71 replication *in vitro*. The virus strain used was the fatal strain, 5865/SIN/00009 (Accession number AF316321; genogroup B4; designated as Strain 41), that was isolated from patients during the HFMD outbreak in October 2000 in Singapore. A specific region of the EV71

genome was targeted for silencing through RNAi. The region targeted was the 3D polymerase region. That particular region of the genome was chosen because it is not prone to mutation.

In a previous study researched by Tan E. L. *et al.*, 19mer siRNA was used to silence EV71 replication. The siRNA used in this study were of three different lengths; 19, 27 and 29 nucleotides long. This leads to the second objective of the study, which is to compare the effectiveness of different lengths of siRNA. According to the theory of RNAi, the 19mer siRNA will not undergo processing by the Dicer molecule because 19mer siRNA is considered as short double-stranded RNA. Thus, the 19mer siRNA will bypass the first processing step and enter directly into the second step, which is being mounted on to the RISC complex. The 27mer siRNA and 29mer siRNA will undergo the entire RNAi pathway without bypassing any step. The three siRNA were transfected at different concentrations to show that gene silencing with siRNA is concentration dependent.

To effectively fulfill the two objectives, western blot and plaque assay were carried out. The results were compared to determine the efficacy of the three siRNA at different concentrations.

## 2. Background

### 2.1 Enteroviruses

The Picornavirus, one of the smallest viruses in the world in terms of size and yet has great genetic complexities, is a large family of viruses [Melnick, 2004]. Its size is about 28 nanometers and has a genome size of approximately 7400 nucleotides [Schnurr, 1999]. Picornaviruses are generally classified to six genera; enteroviruses, rhinoviruses, hepatoviruses, parechovirus, foot-and-mouth disease viruses and cardioviruses [Melnick, 2004]. In the enterovirus genus, it is classified to two main groups; human enterovirus and non-human enterovirus [Melnick, 2004]. Non-human enteroviruses infect a wide variety of animals including bovine, rodent and swine [Melnick, 2004]. Human enteroviruses are sub-classified to echovirus, poliovirus, coxsackievirus groups A and B and other enteroviruses. However as of 1969, all new enteroviruses are numbered instead of sub-classifying them to echovirus, poliovirus and such [Melnick, 2004]. Under the sub-class other enteroviruses, there are four types numbered 68 to 71. Out of these four types, type 68, 70 and 71 are known to infect humans [Melnick, 2004].

Isolation of human enteroviruses is done by performing cell culture. Cell lines that are commonly used for the isolation of human enteroviruses are Rhabdomyosarcoma (Rd), Buffalo Green Monkey Kidney (BGMK) and Vero [Schnurr, 1999].

Some of the special properties of Picornaviruses are that they are stable at a low pH of 3, with the exception of rhinovirus, and they have an optimal temperature for replication at 37 degrees Celsius [Melnick, 2004]. The human gastrointestinal (GI) tract has a suitable acidic pH and temperature, making it the perfect site of replication and growth for the enteroviruses [Melnick, 2004]. Enterovirus infections begin at the oropharynx or the GI tract [Schnurr, 1999]. They will move on to the lymph nodes and subsequently cause viremia [Schnurr, 1999]. At the viremia stage, the enterovirus now has access to enter any tissue in the body. The target tissues of enteroviruses are the central nervous system

(CNS), the epidermis, the cardiac muscles and the pancreas, where the virus can continue to replicate further [Schnurr, 1999].

## 2.2 EV71 Clinical Manifestations

EV71 is a human enterovirus known to cause the infamous HFMD, which can lead to neurological complications [Chong *et al.*, 2005]. The disease which was first isolated in the stools of an infant in 1969 in California [Chong *et al.*, 2005], mainly affects young children under the age of 5. Patients experience painful exanthema and rashes on their hands, feet and limbs, multiple ulcers in their mouths (Figures 1, 2, 3), particularly the soft palate, gums and tongue [Melnick, 2004; 4) and also fever [Alexander *et al.*, 1994]. Life-threatening symptoms include pulmonary edema [Melnick, 2004; 6) and pulmonary hemorrhage [Melnick, 2004]. If the symptoms are left untreated, the patients could develop severe neurological complications such as encephalitis, aseptic meningitis and acute flaccid paralysis [Chong *et al.*, 2005]. In major outbreaks in Malaysia and Taiwan during 1997 and 1998 respectively, patients who had died from HFMD suffered from pulmonary edema and pulmonary hemorrhage after the onset of brain-stem encephalitis [Hellen, 1995].

However, EV71 is not the only cause of HFMD. Other viruses known to cause HFMD are Coxsackievirus A16 (CA16), Coxsackievirus A5 (CA5) and Coxsackievirus B3 [Oberste *et al.*, 1999]. Out of these other causes of HFMD, the most notable is CA16. Clinically, the herpangina symptoms caused by EV71 and CA16 are virtually indistinguishable but EV71 infection has more association to neurological complications and has much higher fatality rates than CA16 [Kuo *et al.*, 2002].

The neurological presentations of EV71 infections reported include muscle spasms, loss of muscle coordination, paralysis and vomiting [Ziegler *et al.*, 1995]. During an EV71 outbreak in Taiwan in 1998, a study was conducted to determine the symptoms presented by infected patients. It was found that 87% of the patients were under the age of five and

out of the 34 patients which were studied, 30 of them suffered from brain stem



*Figure 1: Exanthema on the hands*

One of the common clinical manifestations of HMFD is the presence of exanthema and rashes on the palm of the hands.

[<http://english.pravda.ru/img/idb/hand21.jpg>]



ADAM

*Figure 2: Exanthema on the feet*

Blister-like formations on the soles of the feet are characteristic symptoms in the HFMD cases. Fluid from the blister-like formations may be taken for diagnostic purposes.  
[\[http://www.nlm.nih.gov/medlineplus/ency/images/ency/fullsize/2312.jpg\]](http://www.nlm.nih.gov/medlineplus/ency/images/ency/fullsize/2312.jpg)



*Figure 3: Multiple ulcers on the tongue*

Painful ulcers in the oral cavity and blisters on palms are typically seen amongst HFMD patients. [[http://www.sgpreschoolzone.com/resources/feature/images\\_hfmd/mouth.jpg](http://www.sgpreschoolzone.com/resources/feature/images_hfmd/mouth.jpg)]

encephalitis while the remaining four patients had either aseptic meningitis or meningomyelitis [Ziegler *et al.*, 1995]. Magnetic resonance image (MRI) scans revealed that EV71 has infiltrated into the medulla, pons and the midbrain and caused necrosis, suggesting that those were the targeted tissues [Ziegler *et al.*, 1995]. However, not all of the patients with brain stem encephalitis tested positive in for EV71 in their cerebral spinal fluid (CSF) samples. The most common sample that tested positive for EV71 using cell culture was throat swabs followed by stool samples [Ziegler *et al.*, 1995]. This further confirms that viral replication occurs in the alimentary canal.

### 2.3 Genomic Structure of EV71

As part of the Picornaviridae family, enterovirus 71 (EV71) is a retrovirus with only one single-positive RNA strand [Chong *et al.*, 2005]. It is a non-enveloped virus with a genome size of 7411 nucleotides [Chong *et al.*, 2005]. Complete sequence of the fatal strain used in this study, 5865/sin/000009 (Accession no. 316321), has been uncovered [Singh *et al.*, 2002].

The genomic structure of EV71 is mainly divided into 5 sections; 5' untranslated region (UTR), P1, P2, P3 and 3' UTR (Figure 4). Its single open reading frame (ORF) is situated at the 3' end of the 5' UTR and the 3' end of the P1 region. The P1 region encodes for four different structural proteins; namely, VP1, VP2, VP3 and VP4. The P2 region encodes for three non-structural proteins, 2A, 2B and 2C, while the P3 region encodes for four non-structural proteins, 3A, 3B, 3C and 3D.

The 5' and 3' UTR can be found in all Picornviruses. While the 3' UTR is basically a poly-A tail variable in length, the 5' UTR is slightly more complicated. It was found in a former research on the 5' UTR of poliovirus, which is also under the Picornavirus family, that 5' UTR plays an important role in RNA synthesis and translation [Alexander *et al.*,





Figure 4: Genomic structure of EV71

The ORF is flanked by 5'UTR and 3'UTR. The P1 region consists of VP4, VP2, VP3 and VP1, the P2 region consists of 2A, 2B and 2C and the P3 region includes 3A, 3B, 3C and 3D. [Lukavesh A. N., 2003]

1994] because it contains the internal ribosomal entry site (IRES), which allows cap and end-independent translation of mRNA [Sarnow, 2003]. Later, it was found that all Picornaviruses contained the IRES in their 5' UTR.

The main portions of the EV71 genome are P1, P2 and P3. They encode for the structural and functional proteins of the virus. Firstly, the P1 region encodes for four of the viral capsid proteins; VP4, VP2, VP3 and VP1. From X-ray diffractions analysis and electron microscopy, the structure of EV71 was revealed have icosahedral symmetry [Hellen, 1995] (Figure 5). Each of the surface lattices is made up of 60 units of capsid proteins [Hellen, 1995] and each of the capsid protein is made up from the four proteins encoded by P1. The layout of each capsid is such that the VP4 protein is kept inside the structure formed by VP1, VP2 and VP3 [Hellen, 1995]. Over the years, VP1 has shown to be of great interest, especially in the development and relation to the immune system. Through comparisons with other Picornaviruses, VP1 is shown to be the most immunodominant of the four structural proteins [Oberste *et al.*, 1999], meaning that it is the most easily-recognized by the immune system.

The next region from the 5' end of the P1 region is the P2 region. This region encodes for three proteins; 2A, 2B and 2C. These proteins are involved in the replication of the EV71 virus. The functions of the 2A protein are to cleave the P3 proteins, specifically the 3C and 3D polypeptides [Kuo *et al.*, 2002], and to initiate the IRES translation system to commence viral translation [Ziegler *et al.*, 1995]. It was also found that Enteroviruses undergo recombination frequently and the 2A region is a hotspot for recombination [Lukashev *et al.*, 2003]. Not much is known about the 2B protein, but recent studies suggests that the Picornavirus 2B protein is a small hydrophobic protein that situates itself in the endoplasmic reticulum (ER) and the Golgi apparatus [de Jong *et al.*, 2008]. The study showed that enterovirus 2B protein is able to bring down the calcium concentrations in the two organelles by forming transmembrane pores and also inhibit protein trafficking [de Jong *et al.*, 2008]. The 2C protein is the most highly conserved



*Figure 5: Electron microscopy of EV71*

Transmission electron microscope image shows the isocahedral shape of EV71. Each surface is made of 60 capsid proteins.

[<http://www.clinical-virology.org/gallery/images/em/enterovirus.gif>]

viral protein of all the Picornavirus proteins and was found to be closely related with the replication complex-associated vesicle, suggesting involvement of the 2C protein with the replication process [Tang *et al.*, 2006].

The P3 region encodes for four polypeptides; 3A, 3B, 3C and 3D. The main polypeptides in this region are 3C and 3D. The 3C protein is a protease that cleaves the P1 polypeptide to yield the four individual structural proteins [Sean P, 2008] and 3D encodes for the RNA-dependent RNA polymerase which EV71 uses for its replication [Sean P, 2008]. 3A and 3B have smaller roles in the EV71 replication process.

#### 2.4 EV71 Epidemiology

Since its discovery in California in 1969, there had been many reports of HFMD outbreaks in Bulgaria, Hungary, Malaysia and Taiwan between late 1990s and most of 2000s [Melnick, 2004; Ho *et al.*, 1999]. Table 1 shows a summary of the epidemiology of EV71.

#### 2.5 Diagnosis of EV71

HFMD is transmitted from human to human through direct contact with EV71, CA16 or any other viruses known to cause HFMD. On a HFMD patient, the viruses can be found on the nose, mouth, hands, feet, stool, saliva and the fluid in exanthema [<http://www.cdc.gov>]. The standard diagnosis of EV71 is through cell culture followed by neutralization test based on the Lim Benyesh-Melnick (LBM) pool [Manzara *et al.*, 2002]. During the 1950s, Lim *et al.* developed a serotypic identification method using the serotype-specific antibodies found in animal serum to neutralize the enteroviruses that they had cultured [Lim *et al.*, 1959]. If the results of the neutralization tests were positive, it would mean that the serum contained the specific antibodies for the enterovirus that it was inoculated with [Lim *et al.*, 1959].

Year	Country	Cases	Deaths
1969-73	California	20	1
1972-73	Australia	49	None
1973	Sweden	195	None
1973	Japan	335	None
1975	Bulgaria	750	44
1977	New York	29	None
1978	Hungary	1550	45
1979	France	5	None
1986	Australia	140	None
1987	Philadelphia	5	None
1987	Hong Kong	5	None
1987	Japan	692	None
1997	Malaysia and Sarawak	2628	41
1998	Taiwan	126109	78
1999	Australia	14	None
2000	Malaysia	1725	None
2000	Singapore	3790	8
2001	Hong Kong	284	None
2005	Vietnam	764	None
2005	Taiwan	60	4
2005	India	>200	None
2005	China Zhejiang	101	None
2006	Brunei	140	None
2006	Sarawak	>13000	13
2006	Singapore	3000	None
2008	Taiwan	311	10
2008	Singapore	21000	1
2008	Vietnam	2000	None
2008	Malaysia	1943	None
2008	China	176321	40

Table 1: An Overview of the Epidemiology of Hand-Foot-Mouth Disease

However, the cell culture method is a long and arduous process that requires at least a week [Tan *et al.*, 2007]. For EV71 patients, time is not a luxury they can afford. In 1989, research was carried out on a diagnosis method using polymerase chain reaction (PCR) [Rotbart, 1989]. In the study, the enteroviruses such as Coxsackieviruses and Echoviruses were collected from the CSF samples of the patients and viral RNA was extracted [Rotbart, 1989]. The region that was to be amplified was near the 5' end of the RNA sense strand [Rotbart, 1989]. Two primers, 20 to 25 nucleotides, and a probe were designed to bind to the 3' end and 5' end and the central part of the targeted region respectively [Rotbart, 1989]. Being RNA viruses, reverse transcription HFMD is transmitted from human to human through direct contact with EV71, CA16 or any other viruses known to cause HFMD. On a HFMD patient, the viruses can be found on the nose, mouth, hands, feet, stool, saliva and the fluid in exanthema [<http://www.cdc.gov>]. The standard diagnosis of EV71 is through cell culture followed by neutralization test based on the Lim Benyesh-Melnick (LBM) pool [Manzara *et al.*, 2002]. During the 1950s, Lim *et al.* developed a serotypic identification method using the serotype-specific antibodies found in animal serum to neutralize the enteroviruses that they had cultured [Lim *et al.*, 1959]. If the results of the neutralization tests were positive, it would mean that the serum contained the specific antibodies for the enterovirus that it was inoculated with [Lim *et al.*, 1959].

However, the cell culture method is a long and arduous process that requires at least a week [Tan *et al.*, 2007]. For EV71 patients, time is not a luxury they can afford. In 1989, research was carried out on a diagnosis method using polymerase chain reaction (PCR) [Rotbart, 1989]. In the study, the enteroviruses such as Coxsackieviruses and Echoviruses were collected from the CSF samples of the patients and viral RNA was extracted [Rotbart, 1989]. The region that was to be amplified was near the 5' end of the RNA sense strand [Rotbart, 1989]. Two primers, 20 to 25 nucleotides, and a probe were designed to bind to the 3' end and 5' end and the central part of the targeted region respectively [Rotbart, 1989]. Being RNA viruses, reverse transcription had to be performed to convert the RNA to DNA before PCR can be conducted [Rotbart, 1989]. Gel electrophoresis was done to identify the result of the PCR run and X-ray film blots

were captured to show the estimated concentration of PCR products through the intensity [Rotbart, 1989]. The use of PCR greatly improved the time taken to diagnose patients [Rotbart, 1989]. This method was supported by another research team in 2000, when an EV71-specific assay was developed to rapidly distinguish patients who are infected by EV71 or CA16 [Brown *et al.*, 2000]. The assay developed exploited the technology of reverse-transcription PCR (RT-PCR) and the region that was amplified was the VP1 region [Brown *et al.*, 2000]. Following 2000, RT-PCR had been widely accepted as a method of diagnosis for EV71, especially during outbreaks (28, 29, 30). The advantages of RT-PCR are numerous compared to the neutralization method. Not only time for diagnosis can be shortened, samples with low viral titre such as CSF can also be used for detection [Rotbart, 1989].

Another method of diagnosis by immunofluorescence assay (IFA) [Ho *et al.*, 1999]. This diagnostic method is used after infecting a monolayer of cultured cells and staining the cells with fluorescent dyes. Cell lines used for viral isolation include Vero, Rd cells and MRC-5 cells [Ho *et al.*, 1999]. As this method is dependent on cell culture, the main problem faced is similar as that faced by the neutralization method; the long time it takes to ‘rule in’ the EV71 infection.

In 2002, detection of IgM in the sera of EV71 patients by enzyme-linked immunosorbent assay (ELISA) proved that it could be effective as a diagnosis method [Tano *et al.*, 2002]. The advantage of using this technique for diagnosis is that it is rapid [Tano *et al.*, 2002]. However, the downside is that the IgM is a pentamer made of five identical subunits, making IgM non-specific due to its multiple antigen-binding sites hence, giving rise to high probability of cross-reactions and false positive results. Furthermore, antibodies collected from an EV71-infected patient would very likely to have the virus bound to it. This makes the ELISA result somewhat unreliable.

With many potential unreliability and problems faced in the diagnostics, it would be quite difficult to provide the right treatment for HFMD patients. Therefore, there is an urgent need for accurate and proper diagnostic method

## 2.6 Treatment for EV71 Infection

There are currently no effective vaccines or antiviral therapies against EV71 [Tan *et al.*, 2006]. Managing and keeping the infection under control can be difficult but it is an important aspect that may mean life or death for the patient.

As with viral infections, cell-mediated immunity is initiated in an attempt to fight off the enterovirus infections [Schnurr, 1999]. The B lymphocytes will produce an antibody specific to the type of enterovirus, making the immunity type-specific and long-lasting [Schnurr, 1999]. Pulmonary edema and pulmonary hemorrhage are the most common cause of death for EV71 patients. In a study on immunological responses during EV71 infection, the fatality rate for pulmonary edema was 64% [Wang *et al.*, 2003]. Autopsy results from patients who had died from pulmonary edema revealed that cardiac function and pulmonary pressure were all normal [Wang *et al.*, 2003]. However it was reported that the concentration of cytokines was elevated those patients, especially interleukin-10 (IL-10), IL-6, IL-13, interferon gamma (IFN- $\gamma$ ) and tumor necrosis factor-alpha (TNF- $\alpha$ ) [Wang *et al.*, 2003]. The white cell count was decreased, particularly for CD4+, CD8+ T cells and natural killer (NK) cells [Wang *et al.*, 2003]. This could be caused by increase in leukocytosis and thrombocytosis [Wang *et al.*, 2003]. Hence, it was suggestive that the pulmonary edema was caused by excessive inflammation in the peripheral and CNS [Wang *et al.*, 2003].

One of the treatments used in the outbreak in Taiwan in 1998 was intravenous immunoglobulins (IVIG) [Wang *et al.*, 2006]. IVIG is used to help patients with low gammaglobulins (hypogammaglobulinaemia) increase their immune responses against infections [Chun *et al.*, 2008]. In the case of EV71, it was administered to boost the immune responses against the EV71 infection. Brain stem encephalitis is one of the severe symptoms of EV71 infection which arise from the increase in cytokines mentioned above. Although IVIG was not reported to have been effective in the treatment of EV71 infection, a study conducted in 2006 showed that IVIG lowered the pro-inflammatory

cytokines IL-4, IL-6 and IL-8 in patients with brain stem encephalitis and pulmonary oedema to the point where they are undetectable with ELISA [Wang *et al.*, 2006].

In recent researches, a group of compounds called ‘WIN’ group was shown to have the most potential as an antiviral drug against EV71. The antiviral activity of ‘WIN’ group compounds is the prevention of virus uncoating after the virus has been bound to the receptor [Peaver *et al.*, 1999]. Pleconaril (VP-63843) is one of the drugs in the ‘WIN’ group which has shown significant effects against enteroviral meningitis [Desmond *et al.*, 2006]. Initially used against the common cold caused by rhinoviruses, which is also in the Picornavirus family, pleconaril is now undergoing Phase III of clinical trials in the United States [Romero, 2001]. The clinical studies had shown that the duration and intensity of enteroviral meningitis symptoms were reduced [Romero, 2001]. However, pleconaril was also shown to have limited effectiveness against EV71 [Peaver *et al.*, 1999].

A more recent study involving Chinese herbal medicine was found to induce interferons and antiviral activities against Japanese encephalitis virus (JEV) and EV71 [Lin *et al.*, 2008]. The active component in this herb is aloe-emodin which significantly activated interferon-stimulated response element and gamma-activated sequence [Lin *et al.*, 2008]. IFN responses are induced naturally in the body during a viral infection. They assist the immune response by activating the NK cells and macrophages. The research group conducted dose-dependent and time-dependent studies using aloe-emodin against JEV and EV71 in cultured cells [Lin *et al.*, 2008]. The replication of these two viruses was inhibited via the interferon signaling responses [Lin *et al.*, 2008]. The cultured cells showed low cytotoxicity to aloe-emodin and significantly up-regulated IFN-stimulated gene expression such as double-stranded RNA protein kinase [Lin *et al.*, 2008]. There was also increased activation of nitric oxide which activates guanylate cyclase, an enzyme that catalyzes the formation of cyclic GMP. Cyclic GMP is known to activate the protein kinases.

## 2.7 RNA Interference

The RNAi pathway, which was discovered by the team of Andrew Fire and Craig Mello [<http://nobelprize.org>], is involved in gene silencing [Berkhout, 2008]. RNAi is triggered when a cell comes across a double-stranded RNA (Figure 6). The double-stranded RNA, which may be a viral RNA or mRNA, is first encountered by Dicer, a protease that processes the long double-stranded RNA to small interfering RNA (siRNA) which is about 19 to 23 nucleotides in length with two-base 3' overhangs [Dykxhoorn *et al.*, 2006]. The siRNA is then mounted the RNA-induced silencing complex (RISC) by the RISC loading complex (RLC) [Dykxhoorn *et al.*, 2006]. RISC constitutes of three main domains; Piwi, Argonaute (Ago2) and Zwille (PAZ) while the RLC has two domains: DCR2 and R2D2 [Dykxhoorn *et al.*, 2006]. R2D2 is a domain which binds to the more thermodynamically-stable end of the siRNA, leaving the less thermodynamically-stable end of the siRNA to bind to DCR2 [Dykxhoorn *et al.*, 2006]. In this manner, R2D2 is responsible for the orientation of the siRNA in RISC. The Ago2 domain in RISC binds to the siRNA on the RLC, thereby removing the siRNA from the RLC domains and transferring it to RISC [Dykxhoorn *et al.*, 2006]. The transfer of siRNA from RLC to RISC is facilitated by Armitage, a DEAD-box helicase [Dykxhoorn *et al.*, 2006]. The siRNA is then unwound to its sense and anti-sense strands and the sense strand will be degraded. The remaining anti-sense strand will act as a guide, leading RISC to the targeted mRNA [Dykxhoorn *et al.*, 2006]. The RISC complex will expose two to eight nucleotides on its surface as recognition to viral mRNA [Dykxhoorn *et al.*, 2006]. Once located, the siRNA will form an A-type helicase with the mRNA, which positions the mRNA to the Ago2 Piwi endonuclease domain for cleavage [Dykxhoorn *et al.*, 2006]. Ago2 cleaves the phosphodiester of the complementary mRNA with Mg<sup>2+</sup> as a catalyst. The viral mRNA is now destroyed and viral replication inhibited. The RISC complex releases the mRNA and is recycled by going through another round of mRNA cleavage [Dykxhoorn *et al.*, 2006].




Figure 6: RNAi pathway

Triggered by double-stranded RNA, RNAi uses a cleaved portion to guide RISC to complementary RNA and cleave it. [Dykxhoorn, D. M., 2006]

In many ways, the RNAi pathway is seen as a potential antiviral treatment. However, viruses are known to mutate frequently. If this is so, the pre-mutated siRNA will be unable to guide the RISC complex to the targeted mRNA. If the mutation is in the central region, the binding of the siRNA to the mRNA will not be affected but the cleavage may be interfered [Dykxhoorn *et al.*, 2006].

## 2.8 siRNA Design

For RNAi to be triggered and optimized, the design of siRNA is of importance as it will affect the effectiveness and potency of gene silencing [Reynolds *et al.*, 2004] (Table 2). One of the more important criteria for effective gene silencing using siRNA is that there has to be low G/C content in the siRNA [Reischl *et al.*, 2008]. In a study of siRNA, highly functional siRNA had G/C content of 36% to 52% [Reischl *et al.*, 2008]. Having a siRNA with G/C content lower than 30% would affect the recognition of siRNA to mRNA while G/C content that is more than 52% would affect the unwinding process [Reynolds *et al.*, 2004]. Administering this criterion alone saw a 1.2% to 3.2% increase in functionality [Reynolds *et al.*, 2004].

The second requirement was to have low internal stability in the 5' anti-sense region. This means that it would be ideal to have A/U saturation in the 5' anti-sense region [Reischl *et al.*, 2008]. It was proven that having low internal stability at this particular region is required for effective silencing, duplex unwinding and entry of anti-sense into the RISC complex [Reischl *et al.*, 2008]. A/U saturation also creates low thermodynamics. In the RNAi mechanism, the R2D2 domain will bind to the thermodynamically-stable end of the siRNA while the less thermodynamically-stable end will be left to the DCR2 domain. There is a bias toward the adenine at the 5' region, making it the less thermodynamically-stable end [Dykxhoorn *et al.*, 2006]. This is the end that DCR2 will bind to. The 3' end tends to have slightly higher saturation of G/C which makes it thermodynamically-stable, allowing R2D2 to bind to it [Dykxhoorn *et al.*, 2006].

The third requirement is to avoid having repeated internal sequences in the siRNA structure. Having many repeated internal sequences will bring about hairpin-like formations within the siRNA instead of a linear structure [Reischl *et al.*, 2008]. Overall, the three requisites described above are used to stabilize the structure and positioning of the siRNA in RISC [Reischl *et al.*, 2008].

It was found in a research conducted by Reynolds *et al.* that siRNA efficiency increased by 30.6% when their siRNA had a uridine in the tenth position [Reynolds *et al.*, 2004; Reischl *et al.* 2008]. The reason behind this is that although Ago2 could cleave anywhere in the target mRNA, there was a bias toward cleavage at the tenth position with the uridine [Reynolds *et al.*, 2004]. Further research was carried out in search of bias and prejudices on the type of nucleotide present at a particular position on the siRNA, and more of such cases were uncovered. Adenosine at position 3 of the sense strand increased the efficiency of Ago2 cleavage of mRNA while guanine at position 13 of the sense strand saw prejudice against the effectiveness of RISC on the target mRNA [Reynolds *et al.*, 2004]. The rationality behind this is still unknown but it was speculated these bias and prejudices affected the binding of RISC to mRNA or the recycling of the RISC complex [Reynolds *et al.*, 2004].

One reason that siRNA is used to trigger RNAi instead of using double-stranded RNA is because double-stranded RNA is known to activate Toll-like receptor (TLR) 3 [Hornung *et al.*, 2005]. Under *in vivo* circumstances, viral replication in a normal individual will trigger TLR3. During viral replication, the virus synthesizes long double-stranded RNA which will be later translated to proteins. These double-stranded RNA will activate TLR3, which has evolved to detect pathogen-specific molecules [Hornung *et al.*, 2005]. TLR3 will in turn trigger the IFN pathway by activating immune response [Hornung *et al.*, 2005]. The activation of IFN is effective in antiviral activity but this does not prove the effectiveness of RNAi. In a study done by Hornung *et al.*, siRNA of different sequences were transfected in plasmacytoid dendritic cells (PDC) to confirm their hypothesis that the sequence of siRNA will affect the triggering of the IFN pathway [Hornung *et al.*, 2005]. PDC were used because they are immune cells that contained

plenty of TLR [Hornung *et al.*, 2005]. At the end of the study, not only was the hypothesis was confirmed, but they also managed to uncover several sequences that trigger the IFN pathway. It was found that the sense strand of the siRNA was responsible for the activation of the IFN pathway; the anti-sense strand was not involved [Hornung *et al.*, 2005]. One of the sequences that activated the IFN pathway was 5' → 3' GUCCUUCAA [Hornung *et al.*, 2005].

The sixth criterion is simple. Avoid any sequences that have homology to unintended targets [Reynolds *et al.*, 2004]. A BLASTn search should be conducted before deciding the sequence of siRNA [Reynolds *et al.*, 2004]. The siRNA could trigger the RNAi pathway against another gene that might be essential for the cell's growth [Reynolds *et al.*, 2004].

Criteria	Rationale
G/C content is to be kept between 36% and 52%	G/C content less than 30% will affect the interaction of siRNA-loaded RISC to target mRNA. GC content more than 56% will affect the unwinding of siRNA.
Low internal stability at the 5' anti-sense region created by A/U saturation	Low internal stability is equivalent to low thermodynamically-stability. The DCR2 domain of the RLC will bind to the less thermodynamic end of the siRNA while the R2D2 domain of the RLC will bind to the more thermodynamic end of the siRNA. Thus, this criterion will affect the orientation of the siRNA in the RLC and RISC.
Avoid repeated sequences within the siRNA	Having repeated sequences within the siRNA structure will increase the chances of hairpin-loop-like formations.
Nucleotide bias to uridine at the 10 <sup>th</sup> position, to adenosine at the 3 <sup>rd</sup> position and against guanine at the 19 <sup>th</sup> position	Ago2 tends to cleave the mRNA at the 10 <sup>th</sup> position where uridine is positioned. The reasons bias toward adenosine and prejudice against guanine are still unknown but it was speculated that it has to do with the binding of RISC to the target mRNA or the recycling of the siRNA-loaded RISC.
Avoid sequences that triggers the IFN pathway such as 5' → 3' GUCCUUCAA	Such sequences trigger the immune system through activation of type-1 IFN and the release of IFN- $\alpha$ and IFN- $\beta$ . The activation of IFN responses indicates that the RNAi pathway was not triggered.
Avoid sequences that have homology to unintended targets	BLASTn search should be conducted to avoid unintentional gene silencing of the wrong target.

Table 2: List of criteria for design of efficient siRNA

### 3. Materials and Methods

#### 3.1 Methodology


The objectives of the project was to determine whether siRNA targeted at the 3D polymerase region of the EV71 genome could be used as a potential antiviral therapy against EV71 and to compare the effectiveness of different lengths of siRNA. To tackle these two objectives, a plan was devised. Firstly, the sequences of the three siRNA were designed to target the 3D polymerase region of the EV71 genome. Next, RD cells were cultured for testing. Upon confluence, the cells were seeding into tissue culture plates for the purposes of either plaque forming unit assays or western blot (Figure 7).

#### 3.2 Maintenance of RD Cells

As mentioned, the cells used for this study is the human myosarcoma cell line, Rhabdomyosarcoma (RD) because they are susceptible to EV71 and EV71 can proliferate well in RD cells. The cells were given generously by Dr Tan Eng Lee from National University of Singapore for the purpose of this research. RD cells were maintained in minimum essential medium (MEM) (Gibco, USA) supplemented with 10% fetal bovine serum (FBS) (Appendix II). The cells were cultured in T25 tissue culture flasks and maintained at 37 degrees Celsius and 5% CO<sub>2</sub>. When the cells were confluent, they were washed with 1X Hank's Balanced Salt Solution (HBSS) (Gibco, USA) or 1X phosphate buffer saline (PBS) to rinse off dead cells, before adding 1X trypsin for trypsinisation. After the cells have detached from the inner surface of the flask, media was added to neutralise the effect of the trypsin and the cells were passaged to new T25 flasks at 1:2 ratio or 1:4 ratio.

#### 3.3 Cryo-preservation of RD Cells

RD cells were preserved in liquid nitrogen to maintain a supply of cells and also to keep the cells in use at a low passage number. Two confluent flasks were required to be frozen



*Figure 7: Methodology*

To tackle the project, three siRNA to be used were first designed based on the targeted regions. Cell culture prepared for the cells needed for experimentation. Plaque forming unit assay was first conducted to determine the viral titre to be used for infection. Cells were transfected and cell viability plaque forming unit assay was conducted to check the inhibitory effects of the siRNA. Western blot was carried out after transfection and infection to confirm the results seen the cell viability plaque forming unit assay.

to one cryovial at any one time. The media from the flasks were aspirated and the cells were washed with 1X HBSS or 1X PBS to remove dead and suspending cells. The cells were then trypsinised with 1mL of 1X trypsin in each flask. When the cells were completely detached from the flask, media was added to neutralise the trypsin and the cell suspension from both flasks was transferred to a 15mL Falcon tube to be centrifuged at 1000 revolutions per minute (rpm) for 10 minutes at 4 degrees Celsius. Meanwhile, 4.5mL of media and 0.5mL of dimethyl sulphoxide (DMSO) were used to prepare 10% freezing media. After centrifugation, the supernatant was discarded and the cell pellet was resuspended in 2mL of freezing media. The cell suspension was transferred into a cryovial and placed in a freezing container (Nalgene®) at -80 degrees Celsius overnight to ensure gradual freezing of the cells before it is transferred to a liquid nitrogen tank.

When cells were needed, the cryovial was retrieved from the liquid nitrogen tank and was thawed immediately at a 37 degrees Celsius water bath. The thawed cell suspension was then transferred to a new T25 flask containing 5mL of media to dilute the toxicity of DMSO in the freezing media.

### 3.4 Design of siRNA

For the study, three lengths of siRNA were used; 19 nucleotides, 27 nucleotides and 29 nucleotides. The sequence of the 19 nucleotides used was the same sequence as that of the 19mer siRNA in a previous study conducted by Tan E.L. *et al.* The 27mer siRNA and 29mer siRNA were synthesized using the 19mer siRNA sequence as a guide. Since the 19mer siRNA was complementary to a target area in the 3D region of the EV71 genome (Appendix I), eight nucleotides downstream of the 19mer target sequence was added to form the 27mer siRNA. The 29mer siRNA sequence was established in a similar way by adding 9 nucleotides upstream and one nucleotide downstream of the 19mer siRNA sequence. To follow the criteria to produce efficient siRNA, the 3' ends of both strands of all three siRNA were added with UU overhangs. A BLAST search was conducted on the determined sequences of the three siRNA to ensure that the siRNA only targeted against the EV71 virus and nothing else. A scrambled sequence of both the 19mer and 29mer

siRNA (19mer Scr and 29mer Scr) with the same base compositions were also synthesized and used as negative controls. The 19mer, 29mer, 19mer Scr and 29mer Scr siRNA were received as generous gifts from Dr. Tan Eng Lee from National University of Singapore. The 27mer siRNA was chemically synthesized by Sigma-Proligo, USA. (Table 3)

### 3.5 Seeding of RD Cells

Upon confluence of the flasks, the RD cells were washed, trypsinised and seeded into each well of a 24-well plate or 6-well plate (Nunc, Germany) at a concentration of  $1 \times 10^5$  cells/mL. The plate was then incubated at 37 degrees Celsius and 5% CO<sub>2</sub> for growth before using for study.

### 3.6 Plaque Forming Unit Assay

The plaque forming unit assay was conducted to determine the concentration of virus to be used for infection of the cells. When the cells seeded in a 24-well plate had reached confluence and were monolayered, media from the wells were aspirated and 100uL of virus serial diluted to different concentrations of 10 times, 100 times, 1000 times and 10,000 times were pipetted into each well. Each dilution was repeated in quintuplets (Appendix III). The cells were incubated at room temperature with the virus for 1 hour before the virus was aspirated and 500uL of carboxymethylcellulose (CMC) agar (Appendix III) in 2X growth media was placed into each well. The plate was incubated for 48 hours at 37 degrees Celsius and 5% CO<sub>2</sub>. After the 48 hours incubation, the CMC agar and viral plaques were removed and the cells were fixed with 4% formalin at room temperature. The formalin was washed away after 30 minutes and the cells were stained with 1% crystal violet for 30 minutes at room temperature. Plaques were seen after the staining procedure and were manually counted. To obtain multiplicity of infection (MOI) of 10, there had to be 100 plaques in the well.

siRNA	Nucleotide sequence	Nucleotide location
19mer	5' – GAAA UUGGCUCGAAUUGUU <b>UU*</b> – 3' 3' – <b>UU</b> CUUUAACCGAGCUUAACAA – 5'	7316 – 7324
27mer	5' – GAAUCUGAGAAA UUGGCUCGAAUUGUU <b>UU</b> – 3' 3' – <b>UU</b> CUUAGACUCUUUAACCGUGCUUAACAA – 5'	7305 – 7324
29mer	5' – AGAAA UUGGCUCGAAUUGUUUUAAAUUA <b>UU</b> – 3' 3' – <b>UU</b> UCUUUAACCGAGCUUAACAAAAUUUAUAAU – 5'	7315 – 7333
19mer Scr	5' – AUUGAAUCGGGCUGUAAUU <b>UU</b> – 3' 3' – <b>UU</b> UAACUUAGCCGACAUUA – 5'	
29mer Scr	5' – AAUAGACUCUGGUGUGAAUAAUUUAU <b>UU</b> – 3' 3' – <b>UU</b> UUAUCUGAGACCACACUUUAUAAAUAUAA – 5'	

\* **UU** are the 3' overhangs

*Table 3: siRNA sequence*

The sequences of 19mer, 27mer and 29mer target the 3D polymerase region of the EV71 genome. The 19mer Scr and 29mer Scr sequences are scrambled sequences of the 19mer and 29mer siRNAs respectively. The scrambled sequences do not target any of the EV71 genes or the RD genes.

### 3.7 Cell Viability Plaque Assay

RD cells were seeded in 24-well plates and serum starved when cell confluence reached 80%. Transfection was carried out 24 hours post serum starvation and infection was performed 24 hours or 48 hours post transfection. Virus was aspirated from the wells at the end of the infection incubation and 2X CMC agar was pipetted into each well (Appendix IV). The plates were incubated at 37 degrees Celsius and 5% CO<sub>2</sub> for 48 hours before the processes of fixation with 4% formalin and staining with 1% crystal violet were executed.


### 3.8 Transfection and Infection of RD cells

Following seeding in 6-well plates, the cells were serum starved with Opti-MEM I (Gibco, USA) overnight. The cells were transfected with Lipofectamine™ 2000CD (Invitrogen, USA) diluted with Opti-MEM I and different concentrations (3nM, 5nM and 10nM) of the five siRNA (19mer, 27mer, 29mer, 19mer Scr and 29mer Scr). The cells were transfected for 24 hours or 48 hours before they were infected with MOI 10 of EV71 for 1 hour (Appendix V). The virus was aspirated and fresh media was supplied to the infected cells in the 6-well plates intended for western blot. The cells were incubated at 37 degrees Celsius and 5% CO<sub>2</sub> for another 24 hours before harvesting.

The media from the wells were aspirated and discarded and each well was filled with 300uL of CelLytic M Cell Lysis Reagent (Sigma, USA). The cells were incubated at room temperature for 15 minutes before the cell lysates were collected in Eppendorf tubes and centrifuged at 12000rcf for 15 minutes. The supernatant was transferred to a fresh set of Eppendorf tubes and stored at -80 degrees Celsius while the cell pellets were discarded.

### 3.9 SDS-PAGE and Western blot

Harvested proteins were ready for electrophoresis using sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Equal volume of sample and 2X loading buffer were mixed and loaded into Ready Gel 10% Tris-HCl Gels (Bio-Rad Laboratories, USA). Once the pre-cast gel was completely loaded and the electrophoresis tank was filled with SDS-PAGE buffer, electrophoresis was run at 80 volts for 120 minutes. The bands were transferred to a nitrocellulose membrane using iBlot<sup>TM</sup> Gel Transfer Device (Invitrogen, USA) and western blot was conducted following the procedures from the WesternBreeze<sup>®</sup> Chromogenic Western Blot Immunodetection Kit (Invitrogen, USA) with the use of EV71 VP1 monoclonal antibody (Chemicon International, USA) at a dilution ratio of 1:5000.



*Figure 8: Timeline of methodology*

Top timeline shows for western blot protocol. Bottom timeline shows for cell viability plaque assay. For both protocols, cells may be transfected up to 48 hours and infection may be delayed for one day.

## 4. Results


### 4.1 Determination of Viral Titre

Before the rest of the experiments could be conducted, the viral titre to be used for the subsequent infections had to be determined. Plaque assay was carried out after seeding using four different dilutions of virus. The virus was serially diluted to 10 times, 100 times, 1000 times and 10,000 times. There were no plaques formed in the wells infected with 10 times and 100 times dilutions of EV71 as almost all the cells had died from the infection (Figure 9). Plaques could be counted in the wells infected at 1000 times dilution. The average number of plaques in each well was 29 (Table 4).

### 4.2 Protection of RD Cells from EV71-Induced Cytopathic Effects (CPE)

The three siRNAs; 19mer, 27mer and 29mer, designed to target the 3D polymerase region of EV71 were transfected to RD cells at three concentrations; 3nM, 5nM and 10nM. A BLAST search conducted showed that all three siRNAs had no homology to human genes and were specific to the target region.

The efficacy of the three siRNAs in inhibiting EV71 replication was first evaluated when the RD cells were infected at a MOI of 10, 48 hours post-transfection. Inhibition of EV71-induced CPE was observed with a concentration of 3nM of three siRNAs. This was significantly different from the cells transfected with scrambled sequences. The siRNAs actively inhibited replication up to 72 hours post-infection (hpi). Transfected at 10nM, EV71-induced CPE were better inhibited than siRNAs transfection at 3nM and 5nM (Figure 10).




*Figure 9: Plaques from plaque forming unit assay*

The figure shows two plaques indicated by the red circles from the plaque forming unit assay. The picture was taken using a microscope camera at 40X magnification.

Number of plaques	Well 1	Well 2	Well 3	Well 4	Well 5	Average number of plaques per well
Plate 1	29	13	27	11	25	21
Plate 2	36	31	43	40	23	34.6
Plate 3	24	28	38	28	26	28.8
Plate 4	34	36	37	26	33	33.2
Average number of plaques per well, per plate						29.4

*Table 4: Plaque count in the wells infected with EV71 diluted to 1000 times*

Plaques were counted macroscopically and verified microscopically. The number of plaques resulted from infection with EV71 virus diluted to 1000 times was 29. Therefore through estimation, the viral dilution used for later part of the experiment was 100 times.



*Figure 10: Inhibition of EV71-induced CPE*


RD cells were transfected with 29mer siRNA at 3nM, 5nM and 10nM before infection at MOI of 10. Morphological changes were observed at 48 hours post-transfection and 24 hours post-infection under a light microscope camera at 40X magnification. (a) untreated and uninfected cells; (b) uninfected cells transfected with 10nM of 29mer; (c) untreated and infected cells; (d) transfection agent treated infected cells; (e) infected cells treated with 3nM of 29mer; (f) infected cells treated with 5nM of 29mer; (g) infected cells treated with 10nM of 29mer; (h) infected cells treated with 10nM of 19mer-Scr. Tests were carried out in two independent tests.

#### 4.3 Inhibition of EV71 Replication by siRNA

Plaque forming unit assay was to observe the inhibitory effects of siRNA on EV71. The RD cells were transfected, infected and supplied with CMC agar to allow formation of plaques. The results of the plaque assay showed decreasing trend in the number of plaques with increasing concentration of transfected siRNA (Figure 11).

After the demonstration of EV71-induced CPE inhibition in the plaque forming unit assay, the next step was to determine the potency of the three siRNAs by studying the inhibitory effects of the three different concentrations of siRNAs transfected. After transfection of the siRNAs, RD cells were infected over the course of 24 hours before harvesting for western blot or staining for plaque assay. The protein detected with western blot was the VP1 structural protein. The protein bands were observed to be less intense as concentration of siRNA transfected increased. The cells transfected with the scrambled sequences were found to have bands at almost the same intensity as the cells that were infected only.

Once the results of the western blot were established, western blot was conducted again on the same set of samples but blotted for  $\beta$ -actin instead of VP1 protein as a loading control to establish the reliability of the results (Figure 12).  $\beta$ -actin is a protein that is expressed in all mammalian cells such as RD cells.



*Figure 11: Cell Viability Plaque Forming Unit Assay*

The figure above shows the average number of plaques formed from the cell viability plaque assay. The most number of plaques were formed at 3nM for all three siRNA and the least number of plaques formed was at 10nM concentration. Comparing among the three siRNA, 19mer had the most number of plaques while 29mer had slightly fewer plaques than 27mer.

(a)

t-Test: Two-Sample Assuming Equal Variances

	19.10	27.10
Mean	4	2
Variance	3.333333	1.333333
Observations	4	4
Pooled Variance	2.333333	
Hypothesized Mean Difference	0	
Df	6	
t Stat	1.85164	
P(T<=t) one-tail	0.056766	
T Critical one-tail	1.94318	
P(T<=t) two-tail	0.113532	
T Critical two-tail	2.446912	

more than 0.05, test is non significant  
there is no significance between 19.10 and 27.10

(b)

t-Test: Two-Sample Assuming Equal Variances

	27.10	29.10
Mean	2	1
Variance	1.333333	0.666667
Observations	4	4
Pooled Variance	1	
Hypothesized Mean Difference	0	
Df	6	
t Stat	1.414214	
P(T<=t) one-tail	0.103516	
t Critical one-tail	1.94318	
P(T<=t) two-tail	0.207031	
t Critical two-tail	2.446912	

more than 0.05, test is non significant  
there is no significance between 27.10 and 29.10

(c)

t-Test: Two-Sample Assuming Equal Variances

	19.10	29.10
Mean	4	1
Variance	3.333333	0.666667
Observations	4	4
Pooled Variance	2	
Hypothesized Mean Difference	0	
Df	6	
t Stat	3	
P(T<=t) one-tail	0.012004	
t Critical one-tail	1.94318	
P(T<=t) two-tail	0.024008	
t Critical two-tail	2.446912	

less than 0.05, test is significant  
there is significance between 19.10 and 29.10

(d)

t-Test: Two-Sample Assuming Equal Variances

	27.3	27.5
Mean	14	4.5
Variance	3.333333	1.666667
Observations	4	4
Pooled Variance	2.5	
Hypothesized Mean Difference	0	
Df	6	
t Stat	8.497058	
P(T<=t) one-tail	7.27E-05	
t Critical one-tail	1.94318	
P(T<=t) two-tail	0.000145	
t Critical two-tail	2.446912	

less than 0.05, test is significant  
there is significance between the 27.3 and 27.5

(e)

t-Test: Two-Sample Assuming Equal Variances

	27.5	27.10
Mean	47	4.5
Variance	1.666667	1.333333
Observations	4	4
Pooled Variance	1.5	

(f)

t-Test: Two-Sample Assuming Equal Variances

	27.3	27.10
Mean	14	2
Variance	3.333333	1.333333
Observations	4	4
Pooled Variance	2.333333	
Hypothesized Mean Difference	0	
df	6	
t Stat	11.10984	

Table 5: Student's T test  
for cell viability plaque assay

The tables above represent the Student's T Test that was conducted to compare the significance between siRNA and concentration transfected (a-c) compares the significance between the type of siRNA transfected at 10nM. (d-f) compares the significance between the concentration transfected for 27mer. Appendix VI contains the Student's T Test table for comparison between concentration for 19mer and 29mer.




Figure 12: Western blot for VP1 and  $\beta$ -actin

The results of the western blot for VP1 and  $\beta$ -actin are shown above. Both blots for VP1 and  $\beta$ -actin are from the same batch of samples. The band size for VP1 is 37kD and the band size for  $\beta$ -actin is 41kD. (a) and (b) are blotted for VP1 protein. (c) and (d) are blotted for  $\beta$ -actin.

## 5. Discussion

### 5.1 Problems Encountered

Cell culture was an important part of the study. Without the maintenance of the RD cells, the rest of the research could not be carried out. One of the major problems encountered was contamination. There were many problems with bacterial contamination in the cell line and the growth media. Gram staining revealed that the bacteria frequently encountered were Gram-positive rods or Gram-negative rods. From the results of the Gram stains, it was concluded that the bacteria were *Bacillus cereus* or *Escherichia coli*.

The issue with contamination was resolved by the improvement of cell culture techniques and the addition of antibiotics into the growth media during media preparation. Techniques such as swabbing hands and gloves with 70% alcohol and changing gloves frequently ensured that the cells were kept within a disinfected area. Another measure to keep the cells free from contamination was the use of deionised water instead of regular tap water to humidify the incubator.

During media preparation, antibiotics were added to prevent the growth of bacteria in the growth media. The antibiotics used were a mixture of Penicillin and Streptomycin. In an aliquot of 50mL of growth media, 50uL of antibiotics were added, making up 1% antibiotics. By deploying these techniques, contamination occurred rarely and the rest of the experiment could proceed.

### 5.2 RNAi and siRNA

RNAi has been exploited many researches against many viruses including human immunodeficiency virus (HIV), Hepatitis B virus and Hepatitis C virus [Huang, 2008]. Some HIV studies have even been proven effective *in vivo* [Kumar *et al.*, 2008]. Previous methods explored involved the use of drugs which have variable effectiveness, such as pleconaril, and may also produce undesirable side effects. As RNAi is a naturally-

occurring pathway in many eukaryotic cells, using it as a weapon against EV71 is idealistic.

Using chemically-synthesized siRNA provides many advantages over plasmid-derived siRNA because they are more stable than natural double-stranded RNA. They do not degrade easily and can remain effective at room temperature. Another advantage of using chemically-synthesized siRNA is that it is ready-to-use and non-immunogenic [Trulnzch *et al.*, 2004]. There is no need for culture of transformed bacteria and harvest of plasmid-derived siRNA, which saves time and reduces the chance of bacterial contamination.

By targeting the 3D region of EV71, there can be no replication as the 3D region encodes for the RNA-dependent polymerase. Removal of the polymerase will guarantee the complete inhibition of the virus replication and translation of viral proteins or enzymes. In a previous study, it was shown that RD cells transfected with siRNA targeting the 3D polymerase region had the most potent antiviral effect as compared to the 2C, 3C and 3'UTR regions [Chong *et al*, 2005]. However, as the RD cells proliferate, the new cells will not have the siRNA in them and become susceptible to the viral infection. Inevitably, there will be cells that succumb to the virus.

### 5.3 Plaque Forming Unit Assay

To establish the concentration of virus needed for later parts of the study, plaque forming unit assay was conducted. The aim was to achieve a MOI of 10, which was derived to be 100 plaques in a 24-well tray using the formula in Table 6. MOI of 10 for EV71 was shown to be the most suitable viral titre for cells to show almost 100% CPE within two days. In the plaque forming unit assay performed, the virus were serially diluted to four concentrations; 10 times, 100 times, 1000 times and 10,000 times. These four concentrations of virus were infected to RD cells seeded in a 24-well plate. Plaques could be seen in the wells that were infected with EV71 diluted to 1000 times and 10,000 times. The wells infected with EV71 diluted to 10 times and 100 times were infected to the point where there were almost no cells left. With virtually no cells left in the wells,

Multiplicity of infection (MOI) is the average number of virus particles infecting each cell

Plaque forming unit (pfu) is a measure of number of infectious virus particles

#### Formula

$$\text{MOI} = \text{pfu} / \text{number of cells}$$

$$\text{Pfu} = \text{number of plaques} / (\text{dilution factor} \times \text{volume (mL)})$$

#### Requirements

Target MOI	10
Number of cells / mL	$1 \times 10^5$
Dilution factor	0.001
Volume (ml)	0.1

#### Calculations

$$\text{Pfu} = 10 \times 1 \times 10^5 = 1 \times 10^6$$

$$\text{Number of plaques} = 1 \times 10^6 \times (0.001 \times 0.5) = 500 \quad (\text{for 6well-plate})$$
$$\text{Number of plaques} = 500 / 5 = 100 \quad (\text{for 24well-plate})^*$$

\*The area of one well in the 6-well plate is approximately 5 times larger than one well in the 24-well plate.

Therefore the number of plaques to be formed in a 24-well plate to achieve a MOI of 10 is 100.

*Table 6: Calculations for Plaque forming unit assay*

The three tables show the formula, requirements and the calculations for the number of plaques needed to achieve MOI of 10 for plaque forming unit assay.

[Capital Biosciences]

plaques cannot be defined and seen. The number of plaques in the wells infected with virus diluted to 1000 times and 10,000 times were 26 and 5 on average respectively. Seeing as the number of plaques formed by the cells in infected at 1000 times dilution is 26, it would mean that the next best dilution factor that can attain close to 100 plaques is the 0.01. Therefore, the virus concentration used for the later parts of the experiment was 100 times dilution.

#### 5.4 Transfection

Serum starvation of the RD cells preceded transfection with siRNA and Lipofectamine™ 2000 and infection with EV71 diluted to 100 times. Lipofectamine™ 2000 is a transfection agent that is widely used by many researchers due to its ease to use [<http://www.biocompare.com>]. However, this transfection agent can also cause cytotoxicity to cells if used at high concentrations [<http://www.biocompare.com>]. The amount of Lipofectamine™ 2000 used in this study was 1.2uL for 24-well plate and 6.0uL for 6-well plate, which was the suitable volume to contain the siRNA and also at suitable concentration such that the cells would not experience cytotoxicity even after 48 hours (Figure 10b). After transfection with Lipofectamine™ 2000, the morphology of the cells was noted to be rounded but returned to its normal spindle shape after a few hours. This was reported to be a normal phenomenon as the cells were picking up the micelles containing the siRNA [<http://www.biocompare.com>].

Similarly, siRNA were also reported to be able to induce cytotoxicity to cells [Persengiev *et al.*, 2004]. To prove that the RD cells underwent CPE as a result of the EV71 infection and not the siRNA or transfection agent, two controls were set up. One of the wells was treated with transfection agent and a scrambled sequence of siRNA while another was treated with transfection agent only. 48 hours post transfection, the cells did not show signs of CPE; they were still intact and adhered to the bottom of the wells.

Besides RNAi, another pathway can also be triggered by double-stranded RNA. This pathway, called protein kinase R (PKR), is involved in a cascade of pathways, triggering

of proteins and enzymes [Garcia *et al.*, 2006] and protection against viral infections [Khabar *et al.*, 2003]. When it is activated by double-stranded RNA or interferon, PKR will be phosphorylated and its levels are up-regulated. The activated PKR will phosphorylate eIF2 $\alpha$ , a cellular protein, which is found downstream of the interferon pathway. Following a cascade of pathways, translation of viral proteins is arrested [Khabar *et al.*, 2003]. To ensure that the siRNA transfected did not trigger the PKR pathway but the RNAi pathway, the maximum length of siRNA used was 29 nucleotides. It was found in a previous study that the PKR pathway is triggered when the cell comes across a double-stranded RNA that is more than 30 nucleotides in length [Kim *et al.*, 2005]. It was also shown in another study that even at 29 nucleotides the cell would trigger the RNAi pathway instead of the PKR pathway [Kim *et al.*, 2005]. Thus, the use of 29mer siRNA still ensures that the RNAi pathway will be triggered.

### 5.5 Cell Viability Plaque Forming Unit Assay

Plaque forming unit assay was performed post transfection to find out if the siRNA could inhibit EV71-induced CPE. As shown by the results, there is a decrease in the number of plaques in the wells as the concentration of siRNA transfected increased. The plaque forming unit assay was carried out in three independent tests and the results for all three assays coincided with each other. This means that synthetic siRNA are capable of inhibiting EV71 replication and that the inhibition was concentration dependent.

The number of plaques also differs among the three siRNAs. The number of plaques formed in the wells transfected with 19mer siRNA was more than those formed in the wells transfected with 27mer and 29mer siRNAs. It shows that 19mer siRNA is not as effective in inhibiting EV71-induced CPE as 27mer and 29mer siRNAs. The Student's T Test performed backs this conclusion. Table 11b and 11c indicates that there is no significance between 27mer and 29mer at 10nM, which meant that the 27mer and 29mer were equally effective at inhibiting EV71-induced CPE. However, plaque formation is rather subjective to the naked eyes. The plaques formed in the wells are not very clearly

defined at macroscopic level and might be misled while counting plaques. Hence, western blot was performed to confirm the results from the cell viability plaque assay.

### 5.6 Western Blot

The RD cells were infected after they have been transfected for 24 hours or 48 hours. Fresh media was placed in the wells and kept for 24 hours after the cells had been infected for one hour. The cells were then harvested and western blot detecting for VP1 protein was carried out. The results of the western blot proved that inhibition of EV71 replication through RNAi was dependent on the concentration of siRNA. As seen from the western blot result, the intensity of the VP1 band was stronger at 3nM than 5nM and 10nM for all three lengths of siRNA (Figure 12). However when the intensities of the 10nM bands were compared against the three siRNA, the sample transfected with 10nM of 19mer siRNA appeared to have the strongest intensity while the sample transfected with 29mer siRNA at an equal concentration appeared to have the weakest intensity. It can be concluded from this that 29mer siRNA is better than 19mer and 27mer siRNA inhibiting EV71 replication. It was established from previous studies that siRNA that bypass the Dicer cleavage step would not be as effective at inhibition as those that go through the step [Tan *et al.*, 2006]. The Dicer cleavage is the step that starts off the RNAi pathway after it double-stranded RNA triggers the cell [Dykxhoorn *et al.*, 2006]. The RLC and RISC will come into the pathway after the double-stranded RNA has been processed by Dicer [Dykxhoorn *et al.*, 2006]. Thus, the processing action of Dicer provides the cue for RLC and RISC to come into play [Dykxhoorn *et al.*, 2006]. Since the double-stranded siRNA is cleaved into siRNA of 19 to 23 nucleotides in length, siRNA that were already 19 to 23 nucleotides long will bypass the Dicer cleavage. As the 27mer and 29mer siRNA underwent the complete RNAi pathway, they were more effective at inhibiting EV71 replication.

To ensure that the trend seen in the western blot results were not due to different loading concentration, western blot was performed again on the same set of samples but blotting for  $\beta$ -actin instead. B-actin is a protein that is found in RD cells and is commonly used as

loading control for western blot, immunocytochemistry and immunoprecipitation [<http://www.exactantigen.com>]. The loading method used for blotting VP1 and  $\beta$ -actin were the same and the results seen on the membrane showed that the intensities of the  $\beta$ -actin bands in all the samples were equal. This indicates that the decreasing intensity of the VP1 band was a result of better inhibitory effects from the increasing concentration of transfected siRNA.

Discussion of the results proved that the inhibitory effects of siRNA were concentration dependent, at least up to 10nM. It was proven in both the cell viability plaque forming unit assay and the western blot for VP1. There was an increasing inhibition with increasing concentration of siRNA transfected. The results also indicated that there was a difference in the EV71-induced CPE inhibition among the three siRNAs. 19mer siRNA, though it had significant inhibitory effects, it had the weakest inhibitory effects among the three siRNA. Being quite short, it evaded the first step initiated by the Dicer protease. The full pathway was not encountered by 19mer.

Besides the obvious difference in intensities between 19mer and the other two siRNAs, a less conspicuous difference in intensity between 27.10 and 29.10 was observed. However the difference in intensity was insignificant and thus, it backed-up the results from the Student's T Test for the cell viability plaque forming unit assay that the inhibitory effect between 27.10 and 29.10 was insignificant.

It can then be concluded that EV71-induced CPE could be inhibited by RNAi using chemically-synthesized siRNAs. The inhibitory effect was concentration dependent at least up to 10nM as seen in the decreasing number of plaques in the cell viability plaque forming unit assay and the decreasing intensities in VP1 protein bands in the western blot. The results from both the cell viability plaque forming unit assay and the western blot also evidenced that 19mer had the worst EV71-induced CPE inhibition while 27mer and 29mer had insignificant differences in EV71-induced CPE inhibition at 10nM.


## 6. Future Developments

Due to the time constraints of this project, there were many other controls that could not be carried out. Given more time and funding, this study could also have been further developed.

### 6.1 Transfection Efficiency

One of the controls that could have been carried to solidify the transfection efficiency of the transfection agent and the siRNA is the MTS assay. The MTS assay is based on the principle of changes in colour caused by the enzymatic reactions [University of Chicago, Medical Center]. The chemical MTS is placed into the wells of the cells and an enzyme, mitochondrial reductase, found in the mitochondria of live cells will reduce the MTS to formazan in the presence of another compound called PMS [Cory *et al.*, 1991]. Since the enzyme that reduces MTS to formazan is only found in live cells, the intensity of the formazan colour is directly proportional to the number of live cells in the wells [University of Chicago, Medical Center]. The intensity is measured using an ELISER plate reader at 490nm as this assay is typically performed on a 96-well plate [Promega]. The results of the MTS assay will be in numerical format. The larger the number, the higher concentration of formazan is found in the wells, which is proportional to number of live cells in the well. This MTS assay can be done after transfection to verify that the cells did not undergo CPE due to the cytotoxic effects of the transfection agent and the siRNA.

To ensure that the siRNA was efficiently transfected into the RD cells, another verification assay could have been conducted. By labelling the siRNA to be transfected with fluorescein isothiocyanate (FITC), the transfected RD cells could be viewed under a fluorescence microscope. FITC is a fluorescent compound that is commonly used for the purpose of antibody and probe labeling [Pierce Biotechnology]. Detection of its fluorescence is usually captured by fluorescence microscopes, flow cytometer and immunofluorescence-based assays such as ELISA [Pierce Biotechnology]. It has an



*Figure 13: Molecular structure of FITC*

[<http://www.piercenet.com/Objects/View.cfm?type=ProductFamily&ID=1E194749-7A41-4FAC-8587-B62ACAD49869>]

excitation wavelength of about 494nm and an emission wavelength of 518nm [Pierce Biotechnology].

If fluorescence is seen within the cell, it can be assured that the cells were successfully transfected with the labeled siRNA. However, if the fluorescence is seen outside the RD cells, it could be concluded that the siRNA were not transfected.

## 6.2 Inhibition Detection Assay

In this study, assays done to prove that siRNA indeed inhibited EV71 replication, western blot and plaque forming unit assay. These two protocols showed different view points of the inhibition. The western blot showed inhibition from the viral point-of-view by blotting for the VP1 protein. Decreasing trends of the VP1 protein indicated that EV71 replication was inhibited based on the concentration of siRNA transfected (Figure 10e, f, g). The plaque forming unit assay demonstrated viral inhibition from the host cells' point-of view. Formation of plaques is dependent on having live cells in the wells. If most of the cells succumb to EV71 infection, no cells will be left behind and the wells would be empty. Decreasing number of plaques was seen from the plaque forming unit assay also meant the increasing number of cells that had not undergone CPE from the virus.

To further bullet-proof the inhibition results, reverse transcription and real-time PCR could have been conducted. Being an RNA virus, the RNA from the virus should first be converted to DNA via reverse transcription before real-time PCR could have been carried out. Real-time PCR was chosen to validate the results because it has the ability to specifically detect for EV71 and could also indicate how much virus was inhibited by studying the Ct values. Ct values represent cycle thresholds, which are the cycle numbers in which the fluorescence is first detected beyond the threshold [Applied Biosystems]. Northern blot is also a possible method of EV71 RNA detection method [University of South Carolina, School of Medicine]. However, northern blot requires a larger quantity of RNA than the samples would allow. Therefore, the better alternative would be to use real-time PCR because it amplifies the small amount of RNA available from each sample.

Real-time PCR was chosen over conventional PCR due to its convenience to retrieve the results. Having to prepare for reverse transcription PCR and then detecting the PCR products in an agarose gel is cumbersome. The PCR products may also degrade before it could be detected in the gel. Furthermore, the intensity of the gel bands can be subjective to the viewer. By using real-time PCR, all the possible problems faced when using conventional PCR could be eliminated.

Real-time PCR works on the principle of heat amplification and fluorescence detection [Applied Biosystems]. Probes that are tagged with fluorescent dyes are placed together with the necessary constituents, such as enzymes, magnesium chloride and dNTP (deoxyribonucleotides). During DNA amplification, the probes bound to the newly synthesized DNA release the fluorophores, allowing them to fluoresce [Applied Biosystems]. The total fluorescence intensity is captured by a detector in the real-time PCR machine after every cycle and is represented as a logarithmic value which is plotted on a graph [Applied Biosystems]. Thus, the amount of fluorescence is directly proportional to the quantity of PCR products. By studying the graph plotted, the concentration of DNA amplicons and the Ct values can be known without proceeding to other protocols. If the Ct value is low, it would mean that there was a high concentration of DNA to begin with, hence the fluorescence threshold can be exceeded quite rapidly [University of South Carolina, School of Medicine]. However, if the Ct value is higher, it would mean that the concentration of DNA was lower. Applying this into the context of the project, a higher Ct value would mean a better inhibition of EV71 replication and a lower Ct value would mean a poor inhibition of EV71.

If reverse transcription real-time PCR was to be carried out, the probe chemistry to be used would be TaqMan probe, a product of Applied Biosystems [CyberGene AB]. Other probe chemistries commonly used for real-time PCR detection are SYBR Green I and Hybridization probe. SYBR Green I is not ideal because it is rather unspecific. SYBR Green I is a fluorescence dye that was previously used in DNA gel electrophoresis to detect double-stranded DNA bands in the gel [Roche Applied Science]. It detects double-stranded DNA by binding to the minor grooves of the DNA double-helix structure

[Roche Applied Science]. This dye's ability to bind to double-stranded DNA makes it unspecific because it binds to all double-stranded DNA. If a mismatch takes place in during PCR, SYBR Green I would still detect it and add it to the fluorescence graph. Hybridization probe chemistry operates on the principle of fluorescence resonance energy transfer (FRET) [Premier Biosoft International]. Two probes, which are complementary to the template and located side-by-side when bound to the template, each contain a dye. One of the probes would be bound to a donor dye while the other has an acceptor dye [Premier Biosoft International]. During the annealing phase of the PCR, the two probes would bind to the template DNA strand and during the extension phase, the polymerase would hydrolyze the two templates. Once the probes are in close proximity, ultraviolet excitation causes the donor dye to transfer energy to the acceptor dye [Premier Biosoft International]. In order to return to the rest stage, the acceptor dye would have to release the energy received from the donor dye, and the energy is released in the form of fluorescence [Premier Biosoft International]. The fluorescence can then be captured by the fluorescence detector. Hybridization probe is accurate owing to the fact that the two probes are highly specific; the dyes will only work if the probes are accurately bound to the template [Premier Biosoft International]. The disadvantage of using hybridization probe is that it requires two dyes on two separate probes. If the concentration of probes used was high, the distance between the probe molecules would be closer and may trigger inappropriate fluorescence. This might lead to the high background fluorescence or unaccepted small peaks in the fluorescence graph.

TaqMan probe is also based on the principle of FRET (65). Unlike the hybridization probe, it uses only one probe for fluorescence to take place. It also uses two dyes but instead of donor and acceptor dyes, it uses a quencher dye and a reporter dye (65). Hence, unlike the hybridization probe which requires the two dyes to be in close proximity to emit fluorescence, no fluorescence is emitted when the quencher and reporter dyes are in close proximity (65). However, TaqMan probe is an oligonucleotide, like the probes in the Hybridization chemistry. The commonly-used reporter dye, 6-carboxy-fluorescein (FAM), is located at the 5' end of the probe and the quencher dye, 6-carboxytetramethyl-rhodamine (TAMRA), is located at the 3' end of the probe [CyberGene AB]. Separated

only by the length of the oligonucleotide, the quencher dye suppresses the fluorescence from the reporter dye. During the annealing phase of the PCR, the polymerase hydrolyzes the probe and the two dyes are released from the probe (65, 66). Now being apart from each other, the reporter dye is no longer quenched and the fluorescence is emitted, which is detected and quantified (65). This is repeated every cycle of the annealing phase and does not interfere with the accumulation of PCR products (65).

### 6.3 Therapeutic Studies

Having proven that the three lengths of siRNA were able to inhibit EV71-induced CPE, the next step would be to test if the same could be said in therapeutic studies. The study conducted showed that siRNA was able to inhibit viral replication in a prophylactic system. Therapeutic studies are important because infection is to be carried out before siRNA is transfected. An analogy to describe the importance of therapeutic studies would be the events that take place when experiencing an illness. Normally, medication is not taken until the symptoms of an illness begin to show. Similarly, if the cells were to be infected before transfection with siRNA, would the RNAi pathway still be able to inhibit viral replication? To answer this question, prophylactic studies could be carried out and inhibition detection assays such as western blot, plaque forming unit assay and real-time PCR could be used as means of measuring the effectiveness of inhibition of EV71 replication.

Therapeutic studies could be carried out using the same methodology as the prophylactic studies, except that infection would take place before the transfection step. Following the timeline shown in Figure 8, infection of the cells using the viral titre determined by plaque forming unit assay would commence after the RD cells had been seeded for 24 hours. The cells would be infected for 24 hours before being transfected with the three different siRNAs at different concentrations. In the therapeutic studies, the serum starvation step would be omitted. Serum starvation was carried out in the prophylactic studies because it weakens the cells, making them more receptive to the transfection agent carrying the siRNA after being starved for several hours. Serum starvation is

omitted in the therapeutic studies because the cells will be weakened by EV71 infection and be receptive to the transfection agent carrying the siRNA. Cells may be stained 24 or 48 hours post transfection for cell viability plaque forming unit assay or harvested for western blot or reverse transcription real-time PCR.

#### 6.4 In vivo Studies

If the therapeutic studies are able to show signs of recovery for the RD cells, *in vivo* studies may be carried out as well. A previous study using 19mer siRNA to trigger the RNAi pathway in mice infected with EV71 were shown to be successful [Tan *et al.*, 2007]. The 19mer siRNA used in that study was targeted at the 3D polymerase region, which is the same as the one targeted in this project. Besides using siRNA, the group also used short hairpin RNA (shRNA) [Tan *et al.*, 2007]. The shRNA, instead of being comprised of two strands of RNA, is made of a single stranded RNA which back folds to bind complementarily to itself, thus forming a hairpin structure. Using that study as a guideline, *in vivo* studies could be replicated using the three siRNAs used in this project.

Newborn mice that were a few days old, suckling mice, could be used for prophylactic testing. In the previous study, the suckling mice were first injected with 10nM of 19mer siRNA before being infected with EV71 virus [Tan *et al.*, 2007]. Within a few days, the infected mice that did not receive siRNA showed signs of acute flaccid paralysis, suffered significant weight loss and died one to two weeks post infection [Tan *et al.*, 2007]. In contrast, the mice that receive siRNA and were infected did not show signs of weight loss [Tan *et al.*, 2007].

Using that study as a guideline, the inhibitory effects of the three siRNAs can be tested. There are two angles to test the effectiveness of siRNA against EV71. The previous study had shown that siRNA were able to inhibit EV71 replication but shRNA were unable to [Tan *et al.*, 2007]. With this finding, the three siRNAs to be used stand a good chance against EV71 replication. So, one of the angles is to test which siRNA is best at inhibiting

than 19mer *in vitro*, can be put to the test to see if they can still exhibit better inhibitory effects than 19mer.

Figure 14: EV71-infected mice



The picture above shows two mice that were used in the study conducted by Tan E.L. *et al.* The mouse on the left was infected with EV71 and suffered severe weight loss and hind limb paralysis. The mouse on the right was not infected. [Tan E. L. *et al.*, 2007]

EV71 infection. In the research conduct by Tan E.L. *et al.*, 19mer siRNA was proven effective in the inhibition of EV71 infection [Tan *et al.*, 2007]. For the future development of this project, 27mer and 29mer, which were proven to be more effective

Another approach to the *in vivo* studies is to test for concentration dependency. In the *in vivo* system, there are more factors to consider. One of the factors that can affect the mice is their immune system. Certainly after being infected with the virus, the immune system of the mice would begin to fight off the infection through activation of the B and T lymphocytes, natural killer (NK) cells, interferon pathways and antigen presentation. These immune responses together with symptoms such as fevers could ultimately destroy the siRNA. The cytotoxic effects of the transfection agent, Lipofectamine™ 2000, and the siRNA could induce more damage to the cells than intended. However, the results of the previous research showed that the mice were able to withstand the cytotoxicity of the siRNA and the transfection agent, and able to survive the EV71 infection.

For the *in vivo* studies, mice that are about three days old are to be used. As discussed and researched by Yu *et al.*, mice that were six days old had developed better immunity against EV71 and were suffered no mortality as compared to the former, thus it would not be suitable to use older mice [Yu *et al.*, 2000]. This finding correlates with the reactions seen in human hosts. As mentioned in the background, children that are below the age of five are more susceptible to EV71 infection than older children and adults. Therefore, it is important to use neonatal mice for *in vivo* studies because it can simulate as closely as possible to the situation in human hosts.

Besides mice, it was shown by Hashimoto *et al.* in 1982 that another animal that is susceptible to EV71 is the cynomolgus monkey [Hashimoto *et al.*, 1982]. However, it would more inconvenient to use monkeys than mice because monkeys are more expensive and more cumbersome to maintain than mice. Experienced with animals, it would be easier to start with smaller animals that are easier to handle.

If given more time and funding, deeper research of this project and the tests explained in this section could lead to the identification of a potential drug to fight against EV71 and possibly save the lives of many children.

## 7. Conclusion

EV71 is one the major cause for HFMD due to its ability to cause severe neurological symptoms and death in children [Chong *et al.*, 2005]. Since its discovery, EV71 had caused outbreaks in many countries and more recently, the Asia-Pacific regions [Melnick, 2004, Ho *et al.*, 1999]. Patients infected with EV71 are at risk for irreversible neurological symptoms, pulmonary oedema and haemorrhage apart from the common symptoms of HFMD, such as ulcers in the oral cavity, fevers, and exanthema on the palms and feet [Melnick, 2004; Singh *et al.*, 2002; Sarnow, 2003; Hellen, 1995].

Current treatments do not target EV71 itself but the symptoms displayed by the victims. However, promising drugs have been found and are undergoing clinical trials. One of the most promising drugs is pleconaril, which was used to treat colds caused by Rhinovirus, a group of viruses that are in the same family as EV71, Picornavirus [Romero, 2001]. Another drug that was shown to be effective against EV71 is aloe-emodin, which can be found in Chinese herbs [Lin *et al.*, 2008]. Aloe-emodin combats EV71 infection by up-regulating interferons and antiviral activities [Lin *et al.*, 2008].

RNAi is a pathway that is widely researched since its discovery due to it potential to be an antiviral therapy. It is triggered by siRNA no longer than 30 nucleotides. This project tested the ability of RNAi to inhibit EV71 using different concentrations and different lengths of siRNA targeting the 3D polymerase of the virus. In a prophylactic system, RD cells were transfected with siRNA and then infected with EV71. Cell viability plaque forming unit assay and western blot were conducted to demonstrate the inhibitory effects of the siRNAs at different concentrations. The results proved that the siRNA are able to inhibit EV71-induced CPE to different degrees based on the concentration of siRNA transfected, with 27mer and 29mer siRNAs having the best inhibitory effects.

This project has shown that RNAi does indeed have the potential to be used as an antiviral therapy. RNAi is favoured because the area of target can be customized to

silence a particular gene. If further developments can be carried out, the three siRNA could be established to be the key to fighting EV71.

## 8. References

1. **Alexander L., Lu H.H., Wimmer E.** 1994. Poliovirus containing picornavirus type 1 and/or type 2 internal ribosomal entry site elements: genetic hybrids and the expression of a foreign gene. *Proc Natl Acad Sci USA.* **91(4)**: 1406 - 1410
2. Applied Biosystems, 2007. Real-time PCR Vs. Traditional PCR [online] Available from:  
[www.appliedbiosystems.com/support/tutorials/pdf/rtpcr\\_vs\\_tradpcr.pdf](http://www.appliedbiosystems.com/support/tutorials/pdf/rtpcr_vs_tradpcr.pdf)  
[Accessed: 31<sup>st</sup> December 2008]
3. **Berkhout B.** 2008. An eye-opener for RNAi therapeutics. *J Formos Med Assoc.* **107(10)**: 749-750
4. Biocompare, 2007. Lipofectamine<sup>TM</sup> Transfection Reagent from Invitrogen [online] Available from:  
<http://www.biocompare.com/Articles/ProductReview/826/ProductReview.html>  
[Accessed: 4<sup>th</sup> January 2009]
5. **Brown B.A., Kilpatrick D.R., Oberste M.S., Pallansch M.A.** 2000. Serotype-specific identification of enterovirus 71 by PCR. *J Clin Virol.* **16(2)**: 107-112
6. **Cardosa M.J., Perera D., Brown B.A., Cheon D., Chan H.M., Chan K.P., Cho H., McMinn P.** 2003. Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the asia-pacific region: comparative analysis of the VP1 and VP4 genes. *Emerg Infect Dis.* **9(4)**: 461-468
7. Center for Disease Control, 2008. Hand, Foot, and Mouth Disease (HFMD) [online] Available from:  
<http://www.cdc.gov/ncidod/dvrd/revb/enterovirus/hfhf.htm>  
[Accessed: 19<sup>th</sup> October 2008]

8. **Chun J.K., Lee T.J., Song T. W., Linton J.A., Kim D.S.** 2008. Analysis of clinical presentations of Bruton disease: A review of 20 years of accumulated data from pediatric patients at Severance Hospital. *Yonsei Med J.* **49**(1): 28-36
9. **Cory A.H., Owen T.C., Barltrop J.A., Cory J.G.** 1991. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. *Cancer Commun.* **3**(7): 207-212
10. CyberGene AB, 2008.TaqMan® Probes [online] Available from :  
<http://www.cybergene.se/TaqManprobes.htm>  
[Accessed: 5<sup>th</sup> January 2009]
11. **de Jong A.S., de Mattia F., Van Dommelen M.M., Lanke K., Melchers W.J., Willems P.H., van Kuppeveld F.J.** (2008) Functional analysis of Picornavirus 2B proteins: effects on calcium homeostasis and intracellular protein trafficking. *J Virol.* **82**(7): 3782-3790
12. **Desmond R.A., Accortt N.A., Talley L., Vilano S.A., Soong S.J., Whitley R.J.** 2006. Enteroviral meningitis: natural history and outcome of pleconaril therapy. *Antimicrob Agents Chemother.* **50**(7): 2409-2414
13. **Dykxhoorn D.M., Lieberman J.** 2006. Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs. *Annu Rev Biomed Eng* **8**: 377-402
14. Exact Antigen, 2008. Beta actin antibody review [online] Available from:  
<http://www.exactantigen.com/review/beta-actin.html>  
[Accessed: 4<sup>th</sup> January 2009]

15. **Garcia M.A., Gil J., Ventoso I., Guerra S., Domingo E., Rivas C., Esteban M.** 2006. Impact of Protein Kinase PKR in Cell Biology: from Antiviral to Antiproliferative Action. *Microbiol Mol Biol Rev.* **70(4)**: 1032-1060
16. **Hashimoto I., Hagiwara A.** 1982. Pathogenicity of poliomyelitis-like disease in monkeys injected orally with enterovirus 71: A model for human infection. *Neuropath Appl Neurobiol.* **8**: 149-156
17. Hellen, C., 1995. Enterovirus structure and assembly. In: H.A. Rotbart, ed., *Human Enterovirus Infections*. ASM Press, pp 155-195
18. **Ho M., Chen E.R., Hsu K.H., Twu S.J., Chen K.T., Tsai S.F., Wang J.R., Shih J.R.** 1999. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. *N Engl J Med.* **341(13)**: 929-935
19. **Hornung V., Guenthner-Biller M., Bourquin C., Ablasser A., Schlee M., Uematsu S., Noronha A., Manohara M., Akira S., de Fouquerolles A., Endres S., Hartmann G.** 2005. Sequence-specific potent induction of INF- $\alpha$  by short interfering RNA in plasmacytoid dendritic cells through TLR7. *Nat Med.* **11(3)**: 263-270
20. **Huang D.D.** 2008. The potential of RNA interference-based therapies for viral treatment. *Curr HIV/AIDS Rep.* **5(1)**: 33-39
21. Invitrogen, 2006. SYBR® Green I Nucleic Acid Gel Stain. [online] Available from: <http://probes.invitrogen.com/media/pis/mp07567.pdf> [Accessed: 6<sup>th</sup> January 2009]
22. **Khabar K.S., Siddiqui Y.M., al-Zoqhaibi F., al-Haj L., Dhalla M., Zhou A., Dong B., Whitmore M., Paranjape J., Al-Ahdal M.N., Al-Mohanna F., Williams B.R., Silverman R.H.** 2003. RNase L mediates transient control of the

- interferon response through modulation of the double-stranded RNA-dependent protein kinase PKR. *J Biol Chem.* **278**(22): 20124-20132
23. **Kim D.H., Behlke M.A., Rose S.D., Chang M.S., Choi S., Rossi J.J.** 2005. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. *Nat Biotechnol.* **23**(2): 222-226
24. **Kumar P., Ban H.S., Kim S.S., Wu H., Pearson T., Greiner D.L., Laouar A., Yao J., Haridas V., Habiro K., Yang Y.G., Jeong J.H., Kim Y.H., Kim S.W., Peipp M., Fey G.H., Manjunath N., Shultz L.D., Lee S.K., Shankar P.** 2008. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. *Cell.* **134**(4): 577-586
25. **Kuo R.L., Kung S.H., Hsu Y.Y., Liu W.T.** 2002. Infection with enterovirus 71 or expression of its 2A protease induces apoptotic cell death. *J Gen Virol.* **83**(Pt 6): 1367-1376
26. **Lim K.A., Benyesh-Melnick M.** 1959. Typing of viruses by combinations of antiserum pools. Application to typing of enteroviruses (coxsackie and echo). *J Immunol.* **84**: 309-317
27. **Lin C.W., Wu C.F., Hsiao N.W., Chang C.Y., Li S.W., Wan L., Lin Y.J., Lin W.Y.** 2008. Aloe-emodin is an interferon-inducing agent with antiviral activity against Japanese encephalitis virus and enterovirus 71. *Int J Antimicrob Agents.* **32**(4): 355-359
28. **Lukashev A.N., Lashkevich V.A., Ivanova O.E., Koroleva G.A., Hinkanen A.E., Ilonen J.** 2003. Recombination in circulating enteroviruses. *J Virol.* **77**(19):10423-10431

29. **Manzara S., Muscillo M., La Rosa G., Marianelli C., Cattani P., Fadda G.** 2002. Molecular identification and typing of enteroviruses isolated from clinical specimens. *J Clin Microbiol.* **40**(12): 4554-4560
30. Melnick, J.L., 2004. Picornaviruses (Enterovirus & Rhinovirus Groups). In: Brooks G.F. ed., *Jawetz, Melnick, & Adlberg's Medical Microbiology*. McGraw-Hill Professional, pp 487-499
31. The Nobel Prize Foundation, 2008. The Nobel Prize for Physiology or Medicine 2006. [online] Available from:  
[http://nobelprize.org/nobel\\_prizes/medicine/laureates/2006/index.html](http://nobelprize.org/nobel_prizes/medicine/laureates/2006/index.html)  
[Accessed 21<sup>st</sup> October 2008]
32. **Oberste M.S., Maher K., Kilpatrick D.R., Pallansch M.A.** 1999. Molecular evolution of the Human Enteroviruses: correlation of serotype with VP1 sequence and application to Picornavirus classification. *J Virol.* **73**(3): 1941-1948
33. **Peaver D.C., Tull T.M., Seipel M.E., Groarke J.M.** 1999. Activity of pleconaril against enterovirus. *Antimicrob Agents Chemother.* **43**(9): 2109-2115
34. Pierce Biotechnology, 2008. FITC and fluorescein dyes. [online] Available from:  
<http://www.piercenet.com/Objects/View.cfm?type=ProductFamily&ID=1E194749-7A41-4FAC-8587-B62ACAD49869>  
[Accessed: 7<sup>th</sup> January 2009]
35. Premier Biosoft International, 2008. TaqMan® Probes [online] Available from:  
[http://www.premierbiosoft.com/tech\\_notes/TaqMan.html](http://www.premierbiosoft.com/tech_notes/TaqMan.html)  
[Accessed: 7<sup>th</sup> January 2009]

36. Technical Bulletin Promega, 2007. CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay [online] Available from:  
<http://www.seoulin.co.kr/upload/biofiles/2003721153630.pdf>  
[Accessed: 6<sup>th</sup> January 2009]
37. **Reischl D., Zimmer A.** 2008. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. *Nanomedicine*.
38. **Reynolds A., Leake D., Boese Q., Scaringe S., Marshall W.S., Khvorova A.** 2004. Rational siRNA design for rna interference. *Nat Biotechnol.* **22(3)**: 326-330
39. Roche Applied Science Technical Note, 2008. Assay formats for use in Real-Time PCR [online] Available from:  
<http://microarrays.ucsd.edu/roche/pdf/Assay%20Formats.pdf>  
[Accessed: 7<sup>th</sup> January 2009]
40. **Romero J.R.** 2001. Pleconaril: a novel antipicornaviral drug. *Expert Opin Investig Drugs.* **10(2)**: 369-379
41. **Rotbart H.A.** 1989. Enzymatic RNA amplification of enteroviruses. *J Clin Microbiol.* **28(3)**: 438-442
42. **Sarnow P.** 2003. Viral internal ribosome entry site elements: novel ribosome-RNA complexes and roles in viral pathogenesis. *J Virol.* **77(5)**: 2801-2806
43. Schnurr D.P., 1999. Enteroviruses. In: Lennette E.H. 3<sup>rd</sup> ed., *Laboratory Diagnosis of Viral Infections*. Informa Health Care, pp 373-385
44. Sean, P., 2008. Coxsackievirus B RNA Replication: Lessons from Poliovirus. In: Tracy, S., ed., *Group B Coxsackieviruses*. Springer, pp 89-113

45. **Sim A.S., Luhur A., Tan T.M., Chow V.T., Poh C.L.** 2005. RNA interference against enterovirus 71 infection. *Virology*. **341(1)**: 72-79
46. **Singh S., Poh C.L., Chow V.T.** 2002. Complete sequence analyses of enterovirus 71 strains from fatal and non-fatal cases of the hand, foot and mouth disease outbreak in Singapore (2000). *Microbiol Immunol*. **46(11)**: 801-808
47. **Persengiev S.P., Zhu X. Green M.R.** 2004. Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). *RNA*. **10(1)**: 12-18
48. **Tan E.L., Tan T.M., Chow V.T., Poh C.L.** 2006. Enhanced potency and efficacy of 29-mer shRNAs in inhibition of enterovirus 71. *Antiviral Res*. **74(1)**: 9-15
49. **Tan E.L., Tan T.M., Tak Kwooung Chow V., Poh C.L.** 2007. Inhibition of Enterovirus 71 in Virus-infected Mice by RNA Interference. *Mol Ther*. **15(11)**: 1931-1938
50. **Tan E.L., Yong L.L., Quak S.H., Yeo W.C, Chow V.T., Poh C.L.** 2007. Rapid detection of enterovirus 71 by real-time TaqMan RT-PCR. *J Clin Virol*. **42(2)**: 203-206
51. **Tang W.F., Yang S.Y., Wu B.W., Jheng J.R., Chen Y.L, Shih C.H., Lin K.H., Lai H.C., Tang P., Horng J.T.** 2006. Reticulon 3 binds the 2C protein of enterovirus 71 and is required for viral replication. *J Biol Chem*. **282(8)**: 5888-5898
52. **Tano Y., Shimizu H., Shiomi M., Nakano T., Miyamura T.** 2002. Rapid serological diagnosis of enterovirus 71 infection by IgM ELISA. *Jpn J Infect Dis*. **55(4)**: 133-135

53. **Trülnzeh B., Wood M.** 2004. Applications of nucleic acid technology in the CNS. *J Neurochem.* **88(2)**: 257-265
54. University of Chicago Medical Center, 2004. MTS Assay (Cell Proliferation). [online] Available from: <http://www.boneandcancer.org/protocole15.htm> [Accessed: 6<sup>th</sup> January 2009]
55. University of South Carolina, School of Medicine, 2007. Real Time PCR. [online] Available from:<http://pathmicro.med.sc.edu/pcr/realtime-home.htm> [Accessed: 7<sup>th</sup> January 2009]
56. **Wang S.M., Lei H.Y., Huang M.C., Su L.Y., Lin H.C., Yu C.K., Wang J.L., Liu C.C.** 2006. Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis. *J Clin Virol.* **37(1)**: 47-52
57. **Wang S.M., Lei H.Y., Huang K.J., Wu J.M., Wang J.R., Yu C.K., Su I.J., Liu C.C.** 2003. Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. *J Infect Dis.* **188(4)**: 564-570
58. **Yu C.K., Chen C.C., Chen C.L., Wang J.R., Liu C.C., Yan J.J., Su I.J.** 2000. Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. *J Biomed Sci.* **7(6)**: 523-528
59. **Ziegler E., Borman A.M., Kirchweger R., Skern T., Kean K.M.** 1995. Foot-and-mouth disease virus Lb proteinase can stimulate rhinovirus and enterovirus IRES-driven translation and cleave several proteins of cellular and viral origin. *J Virol.* **69(9)**: 3465-3474

## 9. Appendices

### Appendix I

#### EV71 Genome Sequence

Sequence 7411 BP; 2000 A; 1766 C; 1794 G; 1851 T; 0 other;	
ttaaaaacagc	tgtgggttgt acccaactcac agggcccacg tggcgcttagc actctggttc
tgcggAACCT	tttgtgcgcct gtttacgcc cgccccccaa tttgcaactt agaagcaata
cacaacactg	atcaacacgca gcatggcgc accagctatg tcttgatcaa gcacttctgt
ttccccgggc	cgagtatcaa tagactgttc acgcggttga aggagaaga gcccgttata
cggctaacta	cttcgagaaa cctagtagca ccattgaagc tgcaagatgt ttgcgtcgcc
acttcccccg	tgttagatcag gtgcgtgagt cactgcaatc cccacggcgc accgtggcag
tggctgcgt	ggcgccctgc ctatgggca acccatagga cgctctaattg tggacatgg
gcaagagtc	tattgagcta gtttagtagtc ctccggccccc tgaatgcggc taatcctaacc
tgtggagcac	atgccttcaa tccagagggt agtgtgtcg aatgggcaac tctgcagcgg
aaccgactac	tttgggtgtc cgtgtttctt tttatcttta cattggctgc ttatgggtgac
gattatagaa	ttgttaccat atagctattt gattggccat ccggtgtgca atagagctat
tatatacctg	tttgtggct ttgttaccact aacctaaaa tctataacca ccctcgattt
tatattaacc	ctcaatacaa tcaaacatgg gtcacaggt gtctactcag cgatccggct
cccacgagaa	ctccaattca gtcacagaag gtcacccat taattacact accatcaact
attacaaaga	ctcctatgtc ggcacagcgg gcaaacagag cctcaagcaa gaccctgata
aatttgctaa	ccctgtcaag gacattttca ctgaaatggc tgcaaccatg aagtctccat
ccgctgaggc	ttgtgttac agtgtcgcc tggcacaact caccattgga aactccacca
tcactacaca	ggaggcggcg aatatcatag tcggttatgg tgagtggccc tcatactgct
ctgatgacga	tgctacagcg gtggacaagc caacgcggcc agatgttca gtgaataggt
tttatacgtt	ggacactaaa ttgtggaaa agtcatccaa ggggtggat tggaaatgttc
ctgatgtact	gactgagacc ggagtcttt gccagaatgc acagtttcac tatttatata
ggtcaggatt	ttgcattcat gtgcaatgtc atgctagcaa gttccatcaa ggagcgttgt
tagtcgttat	acttcagag tatgttataag ggacagtggc aggccggcaca ggaactgagg
acagccaccc	tccttacaaa caaacacaac ctggcgccga tggttttgcg ttgcagcacc
cgtacgtact	cgatgtggg attcctatatacacaattaaac agtgtgcccc cacaatggaa
ttaacctacy	gaccaataac tgtgccacaa taatagtgc gtatatgaac acactgcctt
tcgactctgc	cctgaaccat tgcaactttt ggctgttgtt ggtgcccatt agcccactag
attttgacca	agggcaact ccggtttatcc ctattacaat cactctagct ccaatgtgct
ctgagtttgc	aggtctcaga caggcggtca ctcaagggtt tcccaccgg ccaaaccag
gaacgaatca	attttgacc accgatgacg gtgtctcagc acccattta ccaaatttcc
accccacacc	atgtattcac atacccgggt aagttagaaa cctgcttgc tggtgtcaag
tggagaccat	tcttgagggt aacaatgtac ccacaatgc caccagtctg atgaaaggc
tacgattccc	ggtgtccgcg caagcgggaa aaggtgaatt gtgtccgtg ttttagggccg
accctggaaag	agacggtcca tggcaatcaa caatgtcgaa ccagttgtgt ggatattaca
cccaagtggtc	aggatcactg gaggttactt ttatgttcac cgggtcttc atggccacgg
gtaaaatgtc	catagttac acacccctg gccccctt acccaaagat cggccacag
caatgtggg	cacacatgtt atctgggatt ttggctaca atcatgtc accctgtaa
taccatggat	cagcaacacc cactacagag cgcatgccc ggatggagtg ttgcattact
ataccacagg	actggtagt atctggtatac aaacaaacta cgtggttcca attggggcac
ccaaacacagc	ttacataata gcaactagcgg cagccagaa gaattttacc atgaaactgt
gtaaagacac	cagtacata ttacagacag cctctattca gggagataga gtggcagatg
tgatagagag	ctctatagga gatagtgtga gttagggact tacccagggcc ctggcagctc
caacaggtca	gaacacgcag gtgagcgtc atcgaactaga cactggtgaa gttccagcgc
tccaagctgc	tgaataggg gcatcgtaa atactagtga tgagagtatg attgagacac
gatgcgttct	taattcacac agtacggcag agaccaccct ggacagctc ttcaatgggg
caggcttggt	aggagagata gatctccctc ttgagggatc cactaatcca aatggttatg
ctaattggga	tatagacata actggttacg cacaatgcg caggaaagtg gagctgttca

cctacatgcg	cttgatgct	gaattcactt	ttgttgcgtg	cactcctact	ggtagaggtt	2880
tcccacaatt	acttcagtat	atgtttgtc	ccctgggtc	tcccaaacc	gagtcgttag	2940
aatcaactgc	ttggcagaca	gccacaaacc	cctcagttt	tgtcaagg	actgatcccc	3000
cggcacaggt	ctcagttccg	tcatgtcac	ccgcgagcgc	ttaccagtgg	tttacgacg	3060
ggtacccac	gtttggagaa	cacaacagg	agaaaagacct	tgagtatgga	gcgtgcctta	3120
ataatatgt	ggcacatttc	tcggtgcaaa	ctgtgggtc	atcaaagtcc	aagtatcctt	3180
tgttgtcag	gatataatg	agaatgaagc	atgtcaggc	gtggatacct	cggccgtatgc	3240
gcaaccaaaa	ctacctgtt	aaagccaatc	caaactatgc	cgttaactcc	atcaaaccga	3300
ccggcactag	tcgtactgcc	attactaccc	ttggaaagtt	cggccagca	tctggggcca	3360
tctacgtgg	caactcaga	gtggtaatc	gtcacctcgc	tactcataat	gactgggcga	3420
acctcgtctg	ggaagatagc	tcccgacacc	tattagtgtc	gtctaccacc	gcccaggggct	3480
gtgatacaat	tgcacgtgt	gactgtcaaa	caggagtgt	ctattgtaat	tccaaaagaa	3540
agcactatcc	agtca	tccaaaccca	gcctcatata	tgtggaggt	agcgagttt	3600
accctgctag	ataccaatcg	cacctgatgc	ttgcagcagg	ccactctgag	ccggcgact	3660
gccccggcat	cttaaggtgt	caacatgg	tagttggat	agtgtccacg	gttggcaacg	3720
ggctcggtgg	tttgcgtat	gtgagggatc	tcttgcgtt	ggatgaagag	gcatggagc	3780
aagggtgtc	tgactacatt	aagggtctcg	gtgacgcatt	tggAACAGGT	ttcactgtat	3840
ctgtatccag	ggaagttgaa	gcccctcaga	accacctcat	aggatctgtat	ggagcagtgg	3900
aaaaaatcct	aaagaacctt	attaagctga	tttcagcgt	agtgattgt	attaggagcg	3960
attatgatat	ggtcaccctc	acagcaactt	tagccctgat	tgggtgcata	ggaagtccct	4020
ggcttggat	taaagccaaa	acagcatcca	ttttaggtat	ccccatcgcc	cagaagcaga	4080
gcgccttcttgc	gctaagaaaa	ttaatgata	ttgcgcgt	tgccaagggt	ttagaatgga	4140
tatccaacaa	aattagtaag	ttcattgact	ggctcaggga	gaagattgtt	ccagcagcta	4200
aagagaaagc	agaattttta	accatttga	agcaattacc	actattagag	aaccagatca	4260
cgaacttgg	gcagtcgcgt	gcctcgcaag	aggaccttga	agctatgttt	ggaaatgtgt	4320
catacctcgc	ccatttctgt	cgcaagttcc	aaccattata	cgccacggag	gccaagcggag	4380
tctatgttct	agagaagaga	atgaacaatt	acatgcgtt	caagagcaaa	caccgtattt	4440
aacctgtatg	tctcatcatt	agaggctcac	caggactgg	aaagtccctt	gcgaccggca	4500
tcattgccc	ggccatagca	gacaagtacc	actctagtgt	gtactcactc	ccaccggatc	4560
ctgaccattt	tgacgggtac	aaacagcaag	tggttacagt	tatggatgac	ctgtgccaga	4620
atcctgacgg	caaagacatg	tcatttattt	gccagatgg	atccaccgt	gattttattt	4680
caccaatggc	ttctctcgaa	gaaaaggag	tttcttcac	atctaaattt	gttatcgcat	4740
ccaccaacgc	cagcaacatt	atagtgc	cagtgtctga	ctctgacgcc	attctgtcgca	4800
ggttctacat	ggattgc	attgaggta	cagactcata	caaaacagac	ttgggttagac	4860
tagacgctgg	gccccact	agtgtgtgg	aaagctattc	aacttagaga	caggaaatcc	4920
gcagccact	agtgtgtgg	aaagctattc	aacttagaga	caggaaatcc	aagtcaggt	4980
atagcgtgg	cacagtgg	tctgaactt	ttagagaata	caatagcaga	tccgtattt	5040
gtaacacaat	tga	accatttta	ttccaaggcc	caccaagtt	caggccaaata	5100
ttgaggagaa	gccagcccc	gacgctat	gcgatctcct	tgctagtg	gatagcgagg	5160
aagtgc	atactgtagg	gaacaagg	ggattatccc	tgaactccc	accaatgttg	5220
aacgacatct	taatagagca	gtgctagtc	tgcaatccat	cactactgt	gtgcgtcg	5280
tctca	gtacgtcatt	tacaagctt	ttgcgggtt	tcaagg	tattctggag	5340
ctcccaagca	agtgc	aaggctgtcc	tccgcacggc	aacagtgc	gttcaaggcc	5400
ttgat	cctatcc	ctgaggag	acatcaggca	agtccaaaca	gaccaagggg	5460
attttacat	gttgggtgtc	agggatc	tggctgttct	cccgccggac	tcacagcccg	5520
ggaagactat	ttgggtggaa	cacaactt	tgaacatcct	tgatgc	gagctgg	5580
acgagcagg	cgttattt	gaactc	tggtgcact	agatattaa	aaaaattt	5640
gagatatc	caagttcatt	ccagagac	ttagcggcgc	tagtgc	actctagt	5700
tcaacacaga	acat	atgtcc	tccctgtgg	ggacgtcg	cgtacgggt	5760
tcttgaac	cagt	gaaag	ccaacacata	ggacat	gtacaattt	5820
caggac	tggagg	gttacat	tcggta	tgttgg	cacattgg	5880
gcaac	ccaagg	gttacat	tgaag	ctacttgc	agtatgc	5940
gtgagat	atgggt	cataaca	aaactgg	actaaacatc	aatggacca	6000
ctcg	gttgg	actt	atgtgt	tgaagg	aa	6060
cagt	tttaac	aactaa	cctagat	tgaaca	acc	6120
at	atgtgt	tttta	cacgag	atgaat	atgt	6180
at	atgc	actt	ttgg	acta	gatgag	6240

gctatggcac	tgaaaacctg	gaagcaatag	acctctgcac	tagtgcgtgg	tatccataca	6300
gtgcccttg	tatcaagaaa	agagacattc	tcgaccatc	aaccaggat	gtgtctaaga	6360
tgaaattcta	catggataaa	tacggactag	atctgccata	ctctacctat	gtgaaggatg	6420
aaccttagatc	tctggataaa	atcaagaag	gaaagtacg	cctgatagag	gccagcagct	6480
tgaatgactc	tgtctacctc	agaatgactt	ttggcacct	ttacgaggtg	tttcatgcta	6540
accctggta	tgtgactggc	tcagcagtag	gttgcaccc	agacgtgtt	tggagtaaac	6600
taccgattct	gctgcctggg	tcactcttg	ccttgacta	ctcaggatat	gatgctagtc	6660
tcagcccggt	atggttcagg	gctctagaag	ttgtgttacg	ggagattggg	tattcagagg	6720
aggccgtgtc	cctaataaaaa	ggaatcaacc	acacccacca	tgtgtacccg	aacaaaacat	6780
actgtgtact	tggtggatg	ccctcagggt	gctctggta	ttccatcttc	aattcaatga	6840
tcaataacat	catcattaga	accctttga	tcaaaaccc	taagggata	gacctggatg	6900
agttgaacat	ggtggcctat	ggggacgatg	tgctggccag	ttacccttt	cctattgatt	6960
gccttgaatt	ggctaagact	gccaaagagt	atggtttgc	catgactcct	gcagacaaat	7020
caccctgttt	caatgaagta	acatgggaga	atgctacctt	cctgaagaga	gggttcttgc	7080
cagaccacca	atttccattc	ttaattcacc	ctacgatgcc	catgagagag	atccatgagt	7140
ccattcgtatg	gactaaggac	gcgcgtaaaca	cccaggatca	cgtgcgcctcc	ctgtgtctat	7200
tggcatggca	caatggtaag	gatgaatatg	aaaagttgt	gagtgcatt	agatcagttc	7260
cagttggaaa	agcggtggcc	attcctaact	ttgagaatct	gagaagaaat	tggctcaat	7320
tgttttaata	ttacagttt	aagctgaacc	ccactagaaa	tctggtcgtg	ttaatgacta	7380
gtgggggtaa	atttggata	accggaatag	c			7411

## Appendix II

### Protocol for culture media

MEM (1X)	450mL
Foetal bovine serum	50mL
Penicillin/Streptomycin (1X)	1mL
Total	501mL

### Appendix III

Layout for plaque forming unit assay (determination of viral titre)

Viral Dilution: 10					
Viral Dilution: 100					
Viral Dilution: 1000					
Viral Dilution: 10,000					

## Protocol for CMC Agar

1. 5 grams of CMC powder was dissolved in 250mL of distilled water.
2. The mixture was autoclaved to facilitate complete dissolving.
3. 750mL of culture media was added and mixed gently to create 2X CMC agar

#### Appendix IV

#### Transfection and Infection Layout for Cell Viability Plaque Forming Unit Assay

<u>Appendix 3nM</u>	19mer 3nM	27mer 3nM	27mer 3nM	29mer 3nM	29mer 3nM
Lipofect – 1.2uL OptiMEM – 100uL 19mer siRNA – 150uL (incubate) + OptiMEM – 248.8uL	Lipofect – 1.2uL OptiMEM – 100uL 19mer siRNA – 150uL (incubate) + OptiMEM – 248.8uL	Lipofect – 1.2uL OptiMEM – 100uL 27mer siRNA – 150uL (incubate) + OptiMEM – 248.8uL	Lipofect – 1.2uL OptiMEM – 100uL 27mer siRNA – 150uL (incubate) + OptiMEM – 248.8uL	Lipofect – 1.2uL OptiMEM – 100uL 29mer siRNA – 150uL (incubate) + OptiMEM – 248.8uL	Lipofect – 1.2uL OptiMEM – 100uL 29mer siRNA – 150uL (incubate) + OptiMEM – 248.8uL
19mer 5nM	19mer 5nM	27mer 5nM	27mer 5nM	29mer 5nM	29mer 5nM
Lipofect – 1.2uL OptiMEM – 100uL 19mer siRNA – 2.5uL (incubate) + OptiMEM – 396.3uL	Lipofect – 1.2uL OptiMEM – 100uL 19mer siRNA – 2.5uL (incubate) + OptiMEM – 396.3uL	Lipofect – 1.2uL OptiMEM – 100uL 27mer siRNA – 2.5uL (incubate) + OptiMEM – 396.3uL	Lipofect – 1.2uL OptiMEM – 100uL 27mer siRNA – 2.5uL (incubate) + OptiMEM – 396.3uL	Lipofect – 1.2uL OptiMEM – 100uL 29mer siRNA – 2.5uL (incubate) + OptiMEM – 396.3uL	Lipofect – 1.2uL OptiMEM – 100uL 29mer siRNA – 2.5uL (incubate) + OptiMEM – 396.3uL
19mer 10nM	19mer 10nM	27mer 10nM	27mer 10nM	29mer 10nM	29mer 10nM
Lipofect – 1.2uL OptiMEM – 100uL 19mer siRNA – 5uL (incubate) + OptiMEM – 393.8uL	Lipofect – 1.2uL OptiMEM – 100uL 19mer siRNA – 5uL (incubate) + OptiMEM – 393.8uL	Lipofect – 1.2uL OptiMEM – 100uL 27mer siRNA – 5uL (incubate) + OptiMEM – 393.8uL	Lipofect – 1.2uL OptiMEM – 100uL 27mer siRNA – 5uL (incubate) + OptiMEM – 393.8uL	Lipofect – 1.2uL OptiMEM – 100uL 29mer siRNA – 5uL (incubate) + OptiMEM – 393.8uL	Lipofect – 1.2uL OptiMEM – 100uL 29mer siRNA – 5uL (incubate) + OptiMEM – 393.8uL
19mer Scr 10nM	29mer Scr 10nM	Positive control No infection	No transfect Only infect	Transfection Infection	Transfection No infection
Lipofect – 1.2uL OptiMEM – 100uL 19mer Scr siRNA – 5uL (incubate) + OptiMEM – 393.8uL	Lipofect – 1.2uL OptiMEM – 100uL 29mer Scr siRNA – 5uL (incubate) + OptiMEM – 393.8uL				

Transfection and Infection Layout for Western Blot

siRNA	3nM	5nM	10nM
Lipofect – 6.0uL OptiMEM – 500uL siRNA – 7.5uL (incubate) + OptiMEM – 1986.5uL	Lipofect – 6.0uL OptiMEM – 500uL siRNA – 12.5uL (incubate) + OptiMEM – 1981.5uL	Lipofect – 6.0uL OptiMEM – 500uL siRNA – 25uL (incubate) + OptiMEM – 1969.0uL	Lipofect – 6.0uL OptiMEM – 500uL siRNA – 25uL (incubate) + OptiMEM – 1969.0uL
3nM	5nM	10nM	
<b>Controls</b>			
19mer Scr 10nM	Positive control	Transfection Infection	
Lipofect – 6.0uL OptiMEM – 500uL 19mer Scr siRNA – 25uL (incubate) + OptiMEM – 1969.0uL	No infection	Lipofect – 6.0uL OptiMEM – 500uL (incubate) + OptiMEM – 1994.0uL	No transfect
29mer Scr 10nM	Transfection only	Infection only	
Lipofect – 6.0uL OptiMEM – 500uL 29mer Scr siRNA – 25uL (incubate) + OptiMEM – 1969.0uL	Lipofect – 6.0uL OptiMEM – 500uL (incubate) + OptiMEM – 1994.0uL		

## Appendix VI

### Student's T Tests for 19mer and 29mer

(a)

#### t-Test: Two-Sample Assuming Equal Variances

	19.3	19.5
Mean	17.5	8
Variance	4.333333	2.666667
Observations	4	4
Pooled Variance	3.5	
Hypothesized Mean Difference	0	
Df	6	
t Stat	7.181325	
P(T<=t) one-tail	0.000184	
t Critical one-tail	1.94318	
P(T<=t) two-tail	0.000368	
t Critical two-tail	2.446912	

less than 0.05, test is significant  
there is significance between the 19.3 and 19.5

(b)

#### t-Test: Two-Sample Assuming Equal Variances

	19.5	19.10
Mean	8	4
Variance	2.666667	3.333333
Observations	4	4
Pooled Variance	3	
Hypothesized Mean Difference	0	
df	6	
t Stat	3.265986	
P(T<=t) one-tail	0.00856	
t Critical one-tail	1.94318	
P(T<=t) two-tail	0.01712	
t Critical two-tail	2.446912	

less than 0.05, test is  
significant  
there is significance between the 19.5 and 19.10

(c)

t-Test: Two-Sample Assuming Equal Variances

	19.3	19.10
Mean	17.5	4
Variance	4.333333	3.333333
Observations	4	4
Pooled Variance	3.833333	
Hypothesized Mean Difference	0	
Df	6	
t Stat	9.751254	
P(T<=t) one-tail	3.34E-05	
t Critical one-tail	1.94318	
P(T<=t) two-tail	6.69E-05	
t Critical two-tail	2.446912	

less than 0.05, test is significant  
there is significance between the 19.3 and 19.10

(d)

t-Test: Two-Sample Assuming Equal Variances

	29.3	29.5
Mean	14	3.5
Variance	0.6666667	0.333333
Observations	4	4
Pooled Variance	0.5	
Hypothesized Mean Difference	0	
Df	6	
t Stat	21	
P(T<=t) one-tail	3.8E-07	
t Critical one-tail	1.94318	
P(T<=t) two-tail	7.6E-07	
t Critical two-tail	2.446912	

less than 0.05, test is significant  
there is significance between the 29.3 and 29.5

(e)

t-Test: Two-Sample Assuming Equal Variances

	29.5	29.10
Mean	3.5	1

Variance	0.333333	0.666667
Observations	4	4
Pooled Variance	0.5	
Hypothesized Mean Difference	0	
Df	6	
t Stat	5	
P(T<=t) one-tail	0.001226	
t Critical one-tail	1.94318	
P(T<=t) two-tail	0.002452	
t Critical two-tail	2.446912	

less than 0.05, test is significant  
there is significance between the 29.5 and 29.10

(f)

#### t-Test: Two-Sample Assuming Equal Variances

	29.3	29.10
Mean	14	1
Variance	0.666667	0.666667
Observations	4	4
Pooled Variance	0.666667	
Hypothesized Mean Difference	0	
Df	6	
t Stat	22.51666	
P(T<=t) one-tail	2.51E-07	
t Critical one-tail	1.94318	
P(T<=t) two-tail	5.02E-07	
t Critical two-tail	2.446912	

less than 0.05, test is significant  
there is significance between the 29.3 and 29.10

- (a) shows the comparison between 19.3 and 19.5
- (b) shows the comparison between 19.5 and 19.10
- (c) shows the comparison between 19.3 and 19.10
- (d) shows the comparison between 29.3 and 29.5
- (e) shows the comparison between 29.5 and 29.10
- (f) shows the comparison between 29.3 and 29.10